Clinical Protocol CA209331

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy

(CheckMate 331: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 331)

Study Director / Medical Monitor

Olaf Christensen, MD

This document is the confidential and proprietary information of Bristol-Myers Squibb Company and its global affiliates (BMS). By reviewing this document, you agree to keep it confidential and to use and disclose it solely for the purpose of assessing whether your organization will participate in and/or the performance of the proposed BMS-sponsored study. Any permitted disclosures will be made only on a confidential "need to know" basis within your organization or to your independent ethics committee(s). Any other use, copying, disclosure or dissemination of this information is strictly prohibited unless expressly authorized in writing by BMS. Any supplemental information (eg, amendments) that may be added to this document is also confidential and proprietary to BMS and must be kept in confidence in the same manner as the contents of this document. Any person who receives this document without due authorization from BMS is requested to return it to BMS or promptly destroy it. All other rights reserved. References to BMS in this
protocol may apply to partners to which BMS has transferred obligations, eg, a Contract Research Organization (CRO).
## DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Document</th>
<th>Date of Issue</th>
<th>Summary of Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Protocol</td>
<td>22-Apr-2015</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>
SYNOPSIS
Clinical Protocol CA209331

Protocol Title: An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy

Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational Product(s):

- Nivolumab 240 mg (flat dose) on Day 1 of a 14-day cycle as an IV infusion over 30 minutes.
- Topotecan (subjects enrolled in the United States (US), Europe, South America, Asia [except for Japan]): 1.5 mg/m² administered as 30-minute IV infusion once daily on Days 1 to 5 of a 21-day cycle.
- Amrubicin (subjects enrolled in Japan): 40 mg/m² administered as 5-minute IV infusion once daily on Days 1 to 3 of a 21-day cycle.

Treatment is continued until disease progression, unacceptable toxicity, or other protocol-defined reasons.

Study Phase: 3

Research Hypothesis: Treatment with nivolumab will increase overall survival (OS) as compared with chemotherapy in subjects with relapsed small-cell lung cancer (SCLC) treated with prior platinum-based, first-line chemotherapy.

Objectives:

Primary Objectives
- To compare the OS of nivolumab versus chemotherapy in subjects with relapsed SCLC after platinum-based, first-line chemotherapy.

Secondary Objectives
- To compare the progression free survival (PFS) of nivolumab versus chemotherapy
- To compare the objective response rate (ORR) of nivolumab versus chemotherapy

Date: 22-Apr-2015

Approved v1.0 930089510 1.0
Study Design: This is a randomized, open-label, two-arm, multicenter, Phase 3 study in adult subjects with relapsed SCLC treated with prior platinum-based, first-line chemotherapy. Subjects must have had at least 4 cycles of platinum-based, first-line chemotherapy, or if they received less than 4 cycles, they must have had a best overall response (BOR) of a partial or complete response after completion of chemotherapy.

Study Population:

Key Inclusion Criteria:

Adult men and women with histologically or cytologically confirmed SCLC that recurred or progressed after platinum-based, first-line chemotherapy or chemoradiation therapy. Subjects must have had at least 4 cycles of platinum-based, first-line chemotherapy for either limited or extensive stage disease or if less than 4 cycles, must have had a BOR of at least partial or complete response.

Key Exclusion Criteria:

Active symptomatic central nervous system metastases, documented carcinomatous meningitis, active, known or suspected autoimmune disease, and prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways), topotecan, or amrubicin.
**Study Drug:** includes both Investigational [Medicinal] Products (IP/IMP) and Non-investigational [Medicinal] Products (Non-IP/Non-IMP) as listed below.

<table>
<thead>
<tr>
<th>Study Drug</th>
<th>Potency</th>
<th>IP/Non-IP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nivolumab Solution for Injection</td>
<td>100 mg (10 mg/mL)</td>
<td>IP</td>
</tr>
<tr>
<td>Topotecan</td>
<td>4 mg (1 mg/mL)</td>
<td>IP</td>
</tr>
<tr>
<td>Amrubicin</td>
<td>50 mg (5 mg/mL)</td>
<td>IP</td>
</tr>
</tbody>
</table>

**Study Assessments:** OS is the primary endpoint of the study. OS will be followed continuously while subjects are on the study drugs and every 3 months via in-person or phone contact after subject discontinued the study drugs.

Subjects will be assessed for response by computed tomography (CT) or magnetic resonance imaging (MRI) beginning at 6 weeks (± 5 days) (from the first dose of study treatment) and continuing every 6 weeks (± 5 days) until Week 30 and then every 12 weeks (± 5 days). Tumor assessment will continue until disease progression (or until discontinuation of study drug in patients receiving nivolumab beyond progression), lost to follow-up, withdrawal of study consent, or the study ends. All randomized subjects will be evaluated.

**Statistical Considerations:**

**Sample Size:** Approximately 480 subjects will be randomized at a ratio of 1:1 into two arms: Arm A (nivolumab); Arm B (chemotherapy – ie, topotecan or amrubicin [Japan only]).

The study requires at least 338 deaths to ensure that a two-sided 5% significance level sequential test procedure with one interim analysis will have 90% power to detect a hazard ratio (HR) of 0.7, corresponding to a median OS of 8 vs 11.4 months for the chemotherapy and nivolumab monotherapy treatment arms, respectively.

The formal comparison of OS at interim will allow for early stopping for superiority, and the boundaries for declaring superiority will be derived based on the actual number of deaths using Lan-DeMets α spending function with O’Brien and Fleming type of boundary in EAST v5.4. If the analysis is performed exactly at 237 deaths (70% of the expected number of events at the final analysis), the boundary for declaring superiority would be 0.0148 (or 0.73 with regard to HR boundary, which corresponds to about 3 months improvement in median OS under the assumed control arm hazard function). The boundary for declaring superiority for the final analysis after 338 events would be 0.0455. This would correspond to an observed hazard ratio of 0.8 or less would lead to a statistically significant result; which can be translated to a 2-month improvement in terms of median OS, using same median control assumption. The cumulative power up to interim and final OS analysis will be 61.5% and 90% respectively.

The secondary endpoints PFS and ORR will be tested hierarchically.

Assuming a median PFS on chemotherapy and nivolumab are 3.5 months and 5 months (HR = 0.7) respectively. At the time of interim analysis of OS, it is expected that there will be approximately 371 PFS events. This will provide more than 90% power to detect difference of 1.5 months in median PFS. In addition, approximately 443 PFS events will occur at the time of the final analysis of OS. This gives more than 95% power to detect a treatment difference of 1.5 months with an overall two-sided type 1 error of 0.05.

**Endpoints:** The primary endpoint for the study is OS. It is defined as the time from randomization to the date of death. A subject who has not died will be censored at last known date alive. OS will be followed continuously while subjects are on the study drug and every 3 months via in-person or phone contact after subjects discontinue the study drug. Secondary endpoints include ORR and PFS.

**Analyses:** All hypothesis testing will be two-sided based on a significance level of 0.05 except for OS. A group sequential testing procedure will be applied to OS to control the overall type I error for interim and final analyses. If superiority of OS is demonstrated, a hierarchical hypothesis testing approach for the key secondary endpoints will be
used to preserve a study-wise type I error rate at 0.05. The key secondary endpoints will be tested in the following hierarchical order:

1) PFS  
2) ORR

The formal statistical testing for PFS will take place only if OS is statistically significant and the statistical testing for ORR will take place only if both OS and PFS are statistically significant.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>TITLE PAGE</td>
<td>1</td>
</tr>
<tr>
<td>DOCUMENT HISTORY</td>
<td>3</td>
</tr>
<tr>
<td>SYNOPSIS</td>
<td>4</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>8</td>
</tr>
<tr>
<td>1.2 Research Hypothesis</td>
<td>21</td>
</tr>
<tr>
<td>1.3 Objectives(s)</td>
<td>21</td>
</tr>
<tr>
<td>1.3.1 Primary Objectives</td>
<td>21</td>
</tr>
<tr>
<td>1.3.2 Secondary Objectives</td>
<td>21</td>
</tr>
<tr>
<td>1.4 Product Development Background</td>
<td>22</td>
</tr>
<tr>
<td>1.5 Overall Risk/Benefit Assessment</td>
<td>22</td>
</tr>
<tr>
<td>2 ETHICAL CONSIDERATIONS</td>
<td>22</td>
</tr>
<tr>
<td>2.1 Good Clinical Practice</td>
<td>22</td>
</tr>
<tr>
<td>2.2 Institutional Review Board/Independent Ethics Committee</td>
<td>23</td>
</tr>
<tr>
<td>2.3 Informed Consent</td>
<td>23</td>
</tr>
<tr>
<td>3 INVESTIGATIONAL PLAN</td>
<td>24</td>
</tr>
<tr>
<td>3.1 Study Design and Duration</td>
<td>24</td>
</tr>
<tr>
<td>3.1.1 Study Phases</td>
<td>26</td>
</tr>
<tr>
<td>3.1.1.1 Screening</td>
<td>26</td>
</tr>
<tr>
<td>3.1.1.2 Treatment</td>
<td>27</td>
</tr>
<tr>
<td>3.1.1.3 Follow up</td>
<td>27</td>
</tr>
<tr>
<td>3.2 Post Study Access to Therapy</td>
<td>27</td>
</tr>
<tr>
<td>Date: 22-Apr-2015</td>
<td>8</td>
</tr>
</tbody>
</table>
3.3 Study Population........................................................................................................ 28
  3.3.1 Inclusion Criteria.............................................................................................. 28
  3.3.2 Exclusion Criteria............................................................................................ 30
  3.3.3 Women of Childbearing Potential .................................................................. 32

3.4 Other Restrictions and Precautions...................................................................... 33
  3.4.1 Investigational Product.................................................................................... 38
    4.1.1 Nivolumab.................................................................................................. 38
    4.1.2 Topotecan.................................................................................................. 38
    4.1.3 Amrubicin................................................................................................. 38
  4.1 Non-investigational Product................................................................................ 38
  4.2 Method of Assigning Subject Identification...................................................... 39
    4.2.1 Screening.................................................................................................. 39
    4.2.2 Randomization.......................................................................................... 39
  4.3 Selection and Timing of Dose for Each Subject.................................................. 40
    4.3.1 Dosing Schedule...................................................................................... 40
      4.3.1.1 Nivolumab......................................................................................... 41
      4.3.1.2 Topotecan......................................................................................... 41
      4.3.1.3 Amrubicin......................................................................................... 42
    4.3.2 Dose Modifications and Dose Delays......................................................... 42
      4.3.2.1 Nivolumab......................................................................................... 42
      4.3.2.2 Topotecan......................................................................................... 43
      4.3.2.3 Amrubicin......................................................................................... 45
    4.3.3 Discontinuation Criteria............................................................................... 46
      4.3.3.1 Nivolumab......................................................................................... 46
      4.3.3.2 Topotecan......................................................................................... 47
      4.3.3.3 Amrubicin......................................................................................... 47
    4.3.4 Treatment Beyond Disease Progression....................................................... 48
      4.3.4.1 Nivolumab......................................................................................... 49
      4.3.4.2 Topotecan......................................................................................... 50
      4.3.4.3 Amrubicin......................................................................................... 50
  4.4 Method of Assigning Subject Identification...................................................... 39
    4.4.1 Screening.................................................................................................. 39
    4.4.2 Randomization.......................................................................................... 39
  4.5 Selection and Timing of Dose for Each Subject.................................................. 40
    4.5.1 Dosing Schedule...................................................................................... 40
      4.5.1.1 Nivolumab......................................................................................... 41
      4.5.1.2 Topotecan......................................................................................... 41
      4.5.1.3 Amrubicin......................................................................................... 42
    4.5.2 Dose Modifications and Dose Delays......................................................... 42
      4.5.2.1 Nivolumab......................................................................................... 42
      4.5.2.2 Topotecan......................................................................................... 43
      4.5.2.3 Amrubicin......................................................................................... 45
    4.5.3 Discontinuation Criteria............................................................................... 46
      4.5.3.1 Nivolumab......................................................................................... 46
      4.5.3.2 Topotecan......................................................................................... 47
      4.5.3.3 Amrubicin......................................................................................... 47
    4.5.4 Treatment Beyond Disease Progression....................................................... 48
      4.5.4.1 Nivolumab......................................................................................... 49
      4.5.4.2 Topotecan......................................................................................... 50
      4.5.4.3 Amrubicin......................................................................................... 50
    4.5.5 Treatment of Nivolumab-related Infusion Reactions.................................... 49
    4.6 Blinding/Unblinding........................................................................................ 50
    4.7 Treatment Compliance..................................................................................... 50
    4.8 Destruction of Study Drug.............................................................................. 51
    4.9 Return of Study Drug...................................................................................... 51
  5 STUDY ASSESSMENTS AND PROCEDURES....................................................... 52
    5.1 Flow Chart/Time and Events Schedule............................................................ 52
      5.1.1 Retesting During Screening or Lead-in Period......................................... 62
    5.2 Study Materials............................................................................................... 62
    5.3 Safety Assessments........................................................................................ 62
5.3.1 Imaging Assessment for the Study .......................................................... 62
5.4 Efficacy Assessments ............................................................................... 62
  5.4.1 Primary Efficacy Assessment ............................................................... 63
  5.4.2 Secondary Efficacy Assessment ......................................................... 64
5.5 Pharmacokinetic and Immunogenicity Assessments .............................. 64
5.6 Biomarker Assessments .......................................................................... 65
  5.6.1 Tumor Tissue Specimens ................................................................ 66
     5.6.1.1 Characterization of Tumor Infiltrating Lymphocytes (TILS) and Tumor Antigens .......................................................... 67
     5.6.1.2 DNA and RNA Genomic Assessment ...................................... 68
     5.6.1.3 Tumor Sample Collection Details ............................................ 68
  5.6.2 Peripheral Blood Markers ................................................................ 68
     5.6.2.1 Single Nucleotide Polymorphisms (SNPs) ............................. 69
     5.6.2.2 Serum Soluble Factors ............................................................ 69
     5.6.2.3 Peripheral Blood Mononuclear Cells (PBMCs) ....................... 69
5.7 Outcomes Research Assessments ............................................................ 69
5.8 Other Assessments .................................................................................. 70
  5.8.1 Immunogenicity Assessments ............................................................ 70
6 ADVERSE EVENTS .................................................................................... 70
  6.1 Serious Adverse Events ........................................................................ 71
     6.1.1 Serious Adverse Event Collection and Reporting ....................... 72
  6.2 Nonserious Adverse Events ................................................................. 73
     6.2.1 Nonserious Adverse Event Collection and Reporting ............... 73
  6.3 Laboratory Test Result Abnormalities .................................................. 73
  6.4 Pregnancy .............................................................................................. 73
  6.5 Overdose ................................................................................................ 74
  6.6 Potential Drug Induced Liver Injury (DILI) .......................................... 74
  6.7 Other Safety Considerations .................................................................. 74
7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL COMMITTEES ......................................................................................... 75
8 STATISTICAL CONSIDERATIONS ........................................................... 75
  8.1 Sample Size Determination ................................................................... 75
  8.2 Populations for Analyses ....................................................................... 76
  8.3 Endpoints ................................................................................................ 77
     8.3.1 Primary Endpoint(s) ...................................................................... 77
     8.3.2 Secondary Endpoint(s) ................................................................. 77
     8.3.2.1 Progression Free Survival ....................................................... 77
     8.3.2.2 Objective Response Rate ....................................................... 77
  8.4 Analyses .................................................................................................. 79
     8.4.1 Demographics and Baseline Characteristics .............................. 79
     8.4.2 Efficacy Analyses .......................................................................... 79
     8.4.2.1 Methods of Primary Endpoint ............................................... 79
     8.4.2.2 Methods for Secondary Endpoint ......................................... 79
  8.4.3 Safety Analyses .................................................................................. 80
  8.4.4 Pharmacokinetic Analyses ............................................................... 80
8.4.5 Biomarker Analyses ................................................................. 80
  8.4.5.1 Pharmacodynamic Analyses ........................................... 80
  8.4.5.2 Pharmacogenomic Analyses ............................................ 81
8.4.6 Outcomes Research Analyses ............................................... 81
8.4.7 Other Analyses ......................................................................... 82

8.5 Interim Analyses ......................................................................... 82

9 STUDY MANAGEMENT ..................................................................... 82
  9.1 Compliance .................................................................................. 82
    9.1.1 Compliance with the Protocol and Protocol Revisions ............. 82
    9.1.2 Monitoring .............................................................................. 83
      9.1.2.1 Source Documentation ................................................... 83
    9.1.3 Investigational Site Training .................................................. 83
  9.2 Records ...................................................................................... 84
    9.2.1 Records Retention ................................................................. 84
    9.2.2 Study Drug Records .............................................................. 84
    9.2.3 Case Report Forms ............................................................... 85
  9.3 Clinical Study Report and Publications ........................................ 85

10 GLOSSARY OF TERMS .................................................................. 87

11 LIST OF ABBREVIATIONS .............................................................. 88

12 REFERENCES .................................................................................. 92

APPENDIX 1 MANAGEMENT ALGORITHMS ...................................... 94
APPENDIX 2 RECIST 1.1 ................................................................. 102
some individuals, the kinetics of tumor growth may initially outpace anti-tumor immune activity. With sufficient time, the anti-tumor activity will dominate and become clinically apparent. Therefore subjects randomized to nivolumab monotherapy will be allowed to continue study therapy after initial investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST 1.1) defined progression if they are assessed to be deriving clinical benefit and tolerating study drug (Section 4.5.4). Such subjects must discontinue study therapy upon evidence of further progression.

1.2 Research Hypothesis

Treatment with nivolumab will increase OS as compared with chemotherapy in subjects with relapsed SCLC treated with prior platinum-based, first-line chemotherapy.

1.3 Objectives(s)

1.3.1 Primary Objectives

To compare the OS of nivolumab versus chemotherapy in subjects with relapsed SCLC after platinum-based, first-line chemotherapy.

1.3.2 Secondary Objectives

Secondary objectives are:

- To compare the PFS of nivolumab versus chemotherapy
- To compare the ORR of nivolumab versus chemotherapy.
1.4 Product Development Background

Nivolumab is in clinical development for the treatment of subjects with NSCLC, RCC, glioblastoma and other cancer types. Recently, nivolumab was approved for the treatment of patients with advanced squamous NSCLC and melanoma.

In a Phase 1/2 trial in subjects with heavily pretreated SCLC, nivolumab monotherapy showed an ORR of 15%. Study CA209331 will be the first Phase 3 study in the clinical development program for SCLC and will evaluate the efficacy and safety of nivolumab monotherapy, as second-line therapy, in subjects with relapsed SCLC after platinum-based first-line chemotherapy.

1.5 Overall Risk/Benefit Assessment

Subjects with SCLC who relapse or progress after platinum based first-line therapy represent a great unmet medical need. Responses to salvage chemotherapy are short lived and the overall survival benefit of chemotherapy is modest. The clinical activity of nivolumab monotherapy observed to date in SCLC suggests the potential for improved clinical outcomes relative to approved chemotherapy. However, nivolumab has not been directly compared to any approved chemotherapy in SCLC previously. Topotecan, the only approved 2nd line treatment for SCLC in the US and Europe, has a well characterized AE profile consistent with cytotoxic chemotherapy, such as pancytopenia including febrile neutropenia, nausea, fatigue, vomiting, stomatitis, fever, and diarrhea. Amrubicin is approved for SCLC in Japan and its safety profile is characterized as well by pancytopenia including febrile neutropenia. Nivolumab can cause clinically relevant AEs including liver toxicities, thyroiditis, pneumonitis, and diarrhea. The activity and manageable AE profile observed with nivolumab supports a head-to-head evaluation versus chemotherapy in second-line SCLC. To assure an ongoing favorable benefit-risk assessment for subjects enrolled onto CA209331, an independent Data Monitoring Committee (DMC) will be utilized to monitor the activity and safety of nivolumab versus chemotherapy throughout the conduct of the trial.

2 ETHICAL CONSIDERATIONS

2.1 Good Clinical Practice

This study will be conducted in accordance with Good Clinical Practice (GCP), as defined by the International Conference on Harmonisation (ICH) and in accordance with the ethical principles underlying European Union Directive 2001/20/EC and the United States Code of Federal Regulations, Title 21, Part 50 (21CFR50).
The study will be conducted in compliance with the protocol. The protocol and any amendments and the subject informed consent will receive Institutional Review Board/Independent Ethics Committee (IRB/IEC) approval/favorable opinion prior to initiation of the study.

All potential serious breaches must be reported to Bristol-Myers Squibb (BMS) immediately. A serious breach is a breach of the conditions and principles of GCP in connection with the study or the protocol, which is likely to affect, to a significant degree, the safety or physical or mental integrity of the subjects of the study or the scientific value of the study.

Personnel involved in conducting this study will be qualified by education, training, and experience to perform their respective tasks.

This study will not use the services of study personnel where sanctions have been invoked or where there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment).

### 2.2 Institutional Review Board/Independent Ethics Committee

Before study initiation, the investigator must have written and dated approval/favorable opinion from the IRB/IEC for the protocol, consent form, subject recruitment materials (eg, advertisements), and any other written information to be provided to subjects. The investigator or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product labeling information to be provided to subjects and any updates.

The investigator or BMS should provide the IRB/IEC with reports, updates and other information (eg, expedited safety reports, amendments, and administrative letters) according to regulatory requirements or institution procedures.

### 2.3 Informed Consent

Investigators must ensure that subjects are clearly and fully informed about the purpose, potential risks, and other critical issues regarding clinical studies in which they volunteer to participate.

In situations where consent cannot be given to subjects, their legally acceptable representatives (as per country guidelines) are clearly and fully informed about the purpose, potential risks, and other critical issues regarding clinical studies in which the subject volunteers to participate.

BMS will provide the investigator with an appropriate (ie, Global or Local) sample informed consent form which will include all elements required by ICH, GCP and applicable regulatory requirements. The sample informed consent form will adhere to the ethical principles that have their origin in the Declaration of Helsinki.

Investigators must:

1) Provide a copy of the consent form and written information about the study in the language in which the subject is most proficient prior to clinical study participation. The language must be non-technical and easily understood.

2) Allow time necessary for subject or subject's legally acceptable representative to inquire about the details of the study.
3) Obtain an informed consent signed and personally dated by the subject or the subject's legally acceptable representative and by the person who conducted the informed consent discussion.

4) Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent form and any other information to be provided to the subjects, prior to the beginning of the study, and after any revisions are completed for new information.

5) If informed consent is initially given by a subject’s legally acceptable representative or legal guardian, and the subject subsequently becomes capable of making and communicating his or her informed consent during the study, consent must additionally be obtained from the subject.

6) Revise the informed consent whenever important new information becomes available that is relevant to the subject's consent. The investigator, or a person designated by the investigator, should fully inform the subject or the subject's legally acceptable representative or legal guardian, of all pertinent aspects of the study and of any new information relevant to the subject's willingness to continue participation in the study. This communication should be documented.

The confidentiality of records that could identify subjects must be protected, respecting the privacy and confidentiality rules applicable to regulatory requirements, the subjects’ signed ICF and, in the US, the subjects’ signed Health Insurance Portability and Accountability Act (HIPAA) Authorization.

The consent form must also include a statement that BMS and regulatory authorities have direct access to subject records.

Subjects unable to give their written consent (eg, stroke or subjects with or severe dementia) may only be enrolled in the study with the consent of a legally acceptable representative. The subject must also be informed about the nature of the study to the extent compatible with his or her understanding, and should this subject become capable, he or she should personally sign and date the consent form as soon as possible. The explicit wish of a subject who is unable to give his or her written consent, but who is capable of forming an opinion and assessing information to refuse participation in, or to be withdrawn from, the clinical study at any time should be considered by the investigator.

The rights, safety, and well-being of the study subjects are the most important considerations and should prevail over interests of science and society.

3 INVESTIGATIONAL PLAN

3.1 Study Design and Duration

This is a randomized, open-label, two-arm, multicenter, Phase 3 study in adult subjects with relapsed SCLC treated with prior platinum-based, first-line chemotherapy. Subjects must have had at least 4 cycles of platinum-based, first-line chemotherapy, or if they received less than 4 cycles, they must have had a best overall response (BOR) of a partial or complete response after completion of chemotherapy.
Approximately 480 subjects will be randomized in a 1:1 ratio to treatment with either nivolumab (Arm A) or chemotherapy (either topotecan or amrubicin, Arm B) and stratified according to the following factors:

- Response to first-line platinum based treatment: platinum sensitive (progression-free interval ≥ 90 days after completion of platinum therapy) vs platinum resistant (progression-free interval < 90 days after completion of platinum therapy)
- Brain metastases at baseline: yes vs no.

Treatments will be administered as follows:

Arm A:
- Nivolumab 240 mg (flat dose) on Day 1 of a 14-day cycle as an IV infusion over 30 minutes.

Arm B:
- Topotecan (subjects enrolled in the US, Europe, South America, Asia [except for Japan]): 1.5 mg/m² administered as 30-minute IV infusion once daily on Days 1 to 5 of a 21-day cycle.
- Amrubicin (subjects enrolled in Japan): 40 mg/m² administered as 5-minute IV infusion once daily on Days 1 to 3 of a 21-day cycle.

On-study tumor assessments will begin at Week 6 post randomization (± 5 days) and be performed every 6 weeks (± 5 days) until Week 30. After Week 30, tumor assessments will be performed every 12 weeks (± 5 days) until disease progression (or until discontinuation of study drug in subjects receiving nivolumab beyond investigator-assessed progression [Section 4.5.4]), lost to follow-up, withdrawal of study consent, or the study ends.

Enrollment will end after approximately 480 subjects have been randomized.

The primary endpoint of the study is OS.

The study design schematic is presented in Figure 3.1-1.

Accrual duration is expected to be approximately 11 months; overall study duration will be approximately 22.5 months (11 months accrual + minimum follow up of 11.5 months). The study will end when analysis of survival is complete. Additional survival follow-up may continue for up to 5 years from the time of this analysis.

A DMC will be utilized to provide general oversight and safety considerations for this study, CA209331 (Section 7).
**3.1.1 Study Phases**

The study is divided into the following phases: Screening, Treatment, and Follow-up

### 3.1.1.1 Screening

- Screening begins after the subject signs the informed consent form (ICF). Subjects will undergo screening evaluations to determine eligibility within 28 days prior to first dose.
- Tumor tissue (archival or recent tumor biopsy) must be available and received by the central laboratory for correlative studies in order for a subject to be randomized. Subjects must consent to allow the acquisition of tumor tissue by study personnel for performance of the correlative studies.
- Baseline disease or tumor assessments should be performed within 28 days of randomization.
- The screening phase either ends with confirmation of full eligibility and randomization of the subject or with the confirmation that the subject is a screen failure.

---

*a Subjects must have had at least 4 cycles of platinum-based, first-line chemotherapy, or if they received less than 4 cycles of platinum-based first-line chemotherapy, they must have had a best overall response (BOR) of at least a partial or complete response after completion of chemotherapy.

---
Subject is assessed for study eligibility as described in Table 5.1-1.

### 3.1.1.2 Treatment

- The treatment phase begins with the randomization call to the interactive voice response system (IVRS). The subject is randomly assigned to one of the 2 treatment arms. Treatment should begin within 3 business days of randomization.
- Study drug is administered as an IV infusion on Treatment Day 1 of each cycle (frequency is dependent on the treatment arm) until disease progression, discontinuation due to toxicity, withdrawal of consent, or the study ends.
- Subjects will be evaluated for response according to the RECIST 1.1 criteria. Radiographic assessments will be obtained in all treatment arms at Week 6 (± 5 days) and every 6 weeks from Week 6 (± 5 days) for the first 30 weeks, and subsequently every 12 weeks (± 5 days), until disease progression (or until discontinuation of study drug in subjects receiving nivolumab beyond progression), lost to follow-up, withdrawal of study consent, or the study ends.
- Subjects in Arm A may continue treatment beyond investigator-assessed RECIST 1.1-defined progression as defined in Section 4.5.4.
- This phase ends when the subject is discontinued from study drug.

Study assessments are to be collected as outlined in Table 5.1-2 or Table 5.1-3 for subjects randomized to nivolumab monotherapy or chemotherapy, respectively.

### 3.1.1.3 Follow up

- Begins when the decision to discontinue a subject from study drug is made (no further treatment with study drug).
- Follow-up consists of 2 follow-up visits within approximately 100 days of the last dose of study drug followed by survival visits that will continue every 3 months after Follow-up Visit 2 until death, lost to follow-up, or withdrawal of study consent.
- Subjects who discontinue study drug for reasons other than disease progression will continue to have radiographic assessments every 6 weeks (± 5 days) for the first 30 weeks, and subsequently every 12 weeks (± 5 days), until disease progression (or until discontinuation of study drug in subjects receiving nivolumab beyond progression), lost to follow-up, withdrawal of study consent, or the study ends.

Study assessments are to be collected as outlined in Table 5.1-4.

### 3.2 Post Study Access to Therapy

At the conclusion of the study, subjects who continue to demonstrate clinical benefit will be eligible to receive BMS supplied study drug consistent with the original study drug assignment. Study drug will be provided via an extension of the study, a rollover study requiring approval by responsible health authority and ethics committee or through another mechanism at the discretion of the sponsor.
of BMS. BMS reserves the right to terminate access to BMS supplied study drug if any of the following occur: a) the marketing application is rejected by responsible health authority; b) the study is terminated due to safety concerns; c) the subject can obtain medication from a government sponsored or private health program; or d) therapeutic alternatives become available in the local market.

3.3 Study Population

For entry into the study, the following criteria MUST be met.

3.3.1 Inclusion Criteria

1. Signed Written Informed Consent
   
a) Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.

b) Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.

2. Target Population
   
a) Histologically or cytologically confirmed SCLC.

b) Subjects with either limited or extensive disease stage at the initial diagnosis are eligible.

c) Must have recurrence or progression after platinum-based, first-line chemotherapy or chemoradiation therapy for the treatment of limited or extensive disease stage SCLC:
   
i) Subjects must have received at least 4 cycles of platinum-based, first-line chemotherapy for either limited or extensive stage disease or if they received less than 4 cycles, they must have had a best overall response (BOR) of a partial or complete response after completion of chemotherapy.

   ii) Subjects must have had only 1 prior regimen of platinum-based, first-line treatment.

d) Evaluable disease by CT/MRI per RECIST 1.1 criteria (Appendix 2).

e) Subject must have demonstrated disease progression based on at least one tumor assessment done after completion of chemotherapy and prior to randomization. The tumor assessment performed during screening will be used as a baseline for efficacy assessments.

f) A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation, as described in Section 5.6.1. Specimens must be received by the central laboratory prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient.

g) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
h) Subject Re-enrollment: This study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure (ie, subject has not been randomized/has not been treated). If re-enrolled, the subject must be re-consented. Only the screening procedures performed outside of the protocol specified timing (eg, > 28 days) must be repeated.

i) Prior radiotherapy or radiosurgery to metastases of the brain or bone must have been completed at least 2 weeks prior to randomization.

3. Age and Reproductive Status

a) Males and females, ≥ 18 to years of age.

b) Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotrophin) within 24 hours prior to the start of study drug.

c) Women must not be breastfeeding.

d) WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with plus 5 half-lives of nivolumab (half-life up to 25 days) plus 30 days (duration of ovulatory cycle) for a total of 23 weeks post-treatment completion (for subjects treated in Arm A).

WOCBP must also agree to follow instructions for method(s) of contraception for the duration of treatment plus 5-half lives of chemotherapy plus 30 days (duration of ovulatory cycle) for a total of 30 days post treatment completion or a duration specified by the local labels of the chemotherapy drugs received, whichever is longer (for subjects treated with Arm B).

e) Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with nivolumab plus 5 half-lives of nivolumab plus 90 days (duration of sperm turnover) for a total of 31 weeks post treatment completion (for subjects treated in Arm A).

Males who are sexually active with WOCBP must also agree to follow instructions for method(s) of contraception for the duration of treatment with chemotherapy plus 5 half-lives of chemotherapy plus 90 days (duration of sperm turnover) for a total of 90 days post treatment completion or a duration specified by the local labels of the chemotherapy drugs received, whichever is longer or a duration specified by the local labels of the chemotherapy drugs received, whichever is longer (for subjects treated in Arm B).

f) Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However they must still undergo pregnancy testing as described in this section.
the use of highly effective methods of contraception. Highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly.

At a minimum, subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective as listed below:

**HIGHLY EFFECTIVE METHODS OF CONTRACEPTION**

- Male condoms with spermicide\(^{22,23}\)
- Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, injectables, implants and intrauterine devices (IUDs) such as Mirena\(^\text{®}\) by WOCBP subject or male subject’s WOCBP partner. Female partners of male subjects participating in the study may use hormone based contraceptives as one of the acceptable methods of contraception since they will not be receiving study drug
- IUDs, such as ParaGard\(^\text{®}\)
- Tubal ligation
- Vasectomy
- Complete Abstinence*
  *Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs. Female subjects must continue to have pregnancy tests. Acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence.

**LESS EFFECTIVE METHODS OF CONTRACEPTION**

- Diaphragm with spermicide
- Cervical cap with spermicide
- Vaginal sponge
- Male Condom without spermicide
- Progestin only pills by WOCBP subject or male subject’s WOCBP partner
- Female Condom*.
  * A male and female condom must not be used together

**3.3.2 Exclusion Criteria**

1. **Target Disease Exceptions**
   a) Active symptomatic central nervous system (CNS) metastases. Subjects are eligible if CNS metastases have been treated and subjects have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to randomization. In addition, subjects must have been either off corticosteroids, or on a stable or decreasing dose of \(\leq 10\) mg daily prednisone (or equivalent) for at least 2 weeks prior to enrollment.
2. Medical History and Concurrent Diseases
   a) Women who are childbearing potential or breastfeeding
   b) Documented carcinomatous meningitis
   c) Active, known or suspected autoimmune disease. Subjects with an autoimmune paraneoplastic syndrome requiring concurrent immunosuppressive treatment are excluded. However, subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
   d) A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. However, corticosteroids with minimal systemic absorption (inhaled or topical steroids or as specified in Section 3.4.3), and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
   e) Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
   f) Prior treatment with topotecan or amrubicin
   g) Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
   h) All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have been resolved to grade 1 (National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI CTCAE] version 4) or baseline before administration of study drug. Subjects with toxicities attributed to prior anti-cancer therapy that are not expected to resolve and resulted in long lasting sequelae, such as neuropathy after platinum based therapy, are permitted to enroll
   i) Other active malignancy requiring concurrent intervention
   j) Previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
   k) Known medical condition that, in the investigator’s opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results
   l) Treatment with any chemotherapy, biologics for cancer, or investigational therapy within 28 days of first administration of study drug (subjects with prior cytotoxic or investigational products < 4 weeks prior to treatment might be eligible after discussion between investigator and sponsor, if toxicities from the prior treatment have been resolved to CTC grade 1 level)
m) Major surgery or significant traumatic injury that is not recovered at least 14 days before the first dose of study drug

3. Physical and Laboratory Test Findings

a) Positive test for hepatitis B virus (HBV) using HBV surface antigen (HBVsAg) test or positive test for hepatitis C virus (HCV) using HCV ribonucleic acid (RNA) or HCV antibody test indicating acute or chronic infection. Subjects with a positive test for HCV antibody but no detection of HCV RNA indicating no current infection are eligible.

b) Known medical history of testing positive for human immunodeficiency virus (HIV) or known medical history of acquired immunodeficiency syndrome (AIDS)

c) Inadequate hematologic function defined by:
   i) White blood cells (WBCs) < 2000/mm$^3$
   ii) Absolute neutrophil count (ANC) < 1000/mm$^3$, or
   iii) Platelet count < 100,000/mm$^3$, or
   iv) Hemoglobin level < 9 g/dL.

d) Inadequate hepatic function as defined by either:
   i) Total bilirubin level $\geq$ 2.5 times the ULN, or
   ii) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels $\geq$ 2.5 times the ULN or $\geq$ 5 times the ULN if liver metastases are present.

4. Allergies and Adverse Drug Reaction

a) History of allergy or hypersensitivity to any of the study drugs or study drug components

5. Other Exclusion Criteria

a) Prisoners or subjects who are involuntarily incarcerated

b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.

Eligibility criteria for this study have been carefully considered to ensure the safety of the study subjects and that the results of the study can be used. It is imperative that subjects fully meet all eligibility criteria.

3.3.3 Women of Childbearing Potential

A Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. In addition, females under the age of 55 years must have a serum follicle stimulating hormone (FSH) level $> 40$mIU/mL to confirm menopause.
Females treated with hormone replacement therapy, (HRT) are likely to have artificially suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH level. The duration of the washout period is a function of the type of HRT used. The duration of the washout period below are suggested guidelines and the investigators should use their judgement in checking serum FSH levels. If the serum FSH level is > 40 mIU/ml at any time during the washout period, the woman can be considered postmenopausal:

- 1 week minimum for vaginal hormonal products (rings, creams, gels)
- 4 week minimum for transdermal products
- 8 week minimum for oral products

Other parenteral products may require washout periods as long as 6 months.

### 3.4.2 Other Restrictions and Precautions

The potential for overlapping toxicities with radiotherapy and nivolumab currently is not known. Therefore, palliative radiotherapy is not recommended while receiving nivolumab. If palliative radiotherapy to bone metastases is required, then nivolumab should be withheld for at least 1 week before, during, and 1 week after radiation. Subjects should be closely monitored for any potential toxicity during and after receiving radiotherapy, and AEs considered related to radiotherapy should resolve to Grade ≤ 1 prior to resuming nivolumab.
Clinical Protocol
BMS-936558

Only non-target bone lesions that do not include lung tissue in the planned radiation field may receive palliative radiotherapy while on study treatment. Details of palliative radiotherapy should be documented in the source records and case report form (CRF). Details in the source records should include: dates of treatment, anatomical site, dose administered and fractionation schedule, and AEs.

Subjects requiring palliative radiotherapy should be assessed for disease progression. Subjects considered as having progressive disease are required to discontinue study therapy, or in Arm A, if appropriate, continue nivolumab therapy as treatment beyond progression. Administration of additional nivolumab to subjects who experienced disease progression at the time of palliative radiotherapy should follow guidelines specified in Section 4.5.4 Treatment Beyond Disease Progression.

3.4.3 Permitted Therapy

Subjects are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses including doses > 10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.

Subjects receiving topotecan or amrubicin may receive growth factors (including G-CSF and erythropoietin) at the discretion of the investigator.

3.5 Discontinuation of Subjects following any Treatment with Study Drug

Subjects MUST discontinue investigational product (and non-investigational product at the discretion of the investigator) for any of the following reasons:

- Disease progression as assessed by RECIST 1.1 criteria (Appendix 2), unless the subject is assigned to the nivolumab treatment arm and meets criteria for treatment beyond progression (Section 4.5.4).
- Subject’s request to stop study treatment
- Any clinical AE, laboratory abnormality or intercurrent illness which, in the opinion of the investigator, indicates that continued participation in the study is not in the best interest of the subject
- Termination of the study by BMS
- Loss of ability to freely provide consent through imprisonment or involuntarily incarceration for treatment of either a psychiatric or physical (eg, infectious disease) illness
- Additional protocol specified reasons for discontinuations, see Section 4.5.3.

In the case of pregnancy, the investigator must immediately notify the BMS Medical Monitor/designee of this event. In most cases, the study drug will be permanently discontinued in an appropriate manner. If the investigator determines a possible favorable benefit/risk ratio that
warrants continuation of study drug, a discussion between the investigator and the BMS Medical Monitor/designee must occur.

All subjects who discontinue study drug should comply with protocol specified follow-up procedures as outlined in Section 5. The only exception to this requirement is when a subject withdraws consent for all study procedures including post-treatment study follow-up or loses the ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either a psychiatric or physical illness).

If study drug is discontinued prior to the subject’s completion of the study, the reason for the discontinuation must be documented in the subject’s medical records and entered on the appropriate CRF page.

### 3.6 Post Study Drug Study Follow up

In this study, overall survival is a key endpoint of the study. Post study follow-up is of critical importance and is essential to preserving subject safety and the integrity of the study. Subjects who discontinue study drug must continue to be followed for collection of outcome and/or survival follow-up data as required and in line with Section 5 until death or the conclusion of the study. BMS may request that survival data be collected on all randomized subjects outside of the protocol defined window (Table 5.1-4). At the time of this request, each subject will be contacted to determine their survival status unless the subject has withdrawn consent for all contact.

#### 3.6.1 Withdrawal of Consent

Subjects who request to discontinue study drug will remain in the study and must continue to be followed for protocol specified follow-up procedures. The only exception to this is when a subject specifically withdraws consent for any further contact with him/her or persons previously authorized by subject to provide this information. Subjects should notify the investigator of the decision to withdraw consent from future follow-up in writing, whenever possible. The withdrawal of consent should be explained in detail in the medical records by the investigator, as to whether the withdrawal is from further treatment with study drug only or also from study procedures and/or post treatment study follow-up, and entered on the appropriate CRF page. In the event that vital status (whether the subject is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.

#### 3.6.2 Lost to Follow-Up

All reasonable efforts must be made to locate subjects to determine and report their ongoing status. This includes follow-up with persons authorized by the subject as noted above. Lost to follow-up is defined by the inability to reach the subject after a minimum of three documented phone calls, faxes, or emails as well as lack of response by subject to one registered mail letter. All attempts should be documented in the subject’s medical records. If it is determined that the subject has died, the site will use permissible local methods to obtain the date and cause of death.
If investigator’s use of third-party representative to assist in the follow-up portion of the study has been included in the subject’s informed consent, then the investigator may use a Sponsor-retained third-party representative to assist site staff with obtaining subject’s contact information or other public vital status data necessary to complete the follow-up portion of the study. The site staff and representative will consult publicly available sources, such as public health registries and databases, in order to obtain updated contact information. If after all attempts, the subject remains lost to follow-up, then the last known alive date as determined by the investigator should be reported and documented in the subject’s medical records.

4 STUDY DRUG

Study drug includes both Investigational [Medicinal] Product (IP/IMP) and Non-investigational [Medicinal] Product (Non-IP/Non-IMP). All study drugs are listed in Table 4-1.
Table 4-1: Study Drugs for BMS-936558 - Treatment Phase

<table>
<thead>
<tr>
<th>Product Description / Class and Dosage Form</th>
<th>Potency</th>
<th>IP/Non-IMP</th>
<th>Blinded or Open Label</th>
<th>Packaging/ Appearance</th>
<th>Storage Conditions (per label)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nivolumab Solution for Injection&lt;sup&gt;a&lt;/sup&gt;</td>
<td>100 mg (10 mg/mL)</td>
<td>IP</td>
<td>Open Label</td>
<td>10 mL per vial/ 5 or 10 vials per box</td>
<td>2° to 8°C. Protect from light and freezing</td>
</tr>
<tr>
<td>Topotecan hydrochloride concentrate for solution for infusion&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4 mg (1 mg/mL)</td>
<td>IP</td>
<td>Open Label</td>
<td>4 mg per vial/ 1 or 5 vials per box</td>
<td>Store at 2° to 8°C. protect from freezing and light. Store in outer carton.</td>
</tr>
<tr>
<td>Amrubicin hydrochloride powder for solution for injection&lt;sup&gt;b&lt;/sup&gt;</td>
<td>50 mg (5 mg/mL)</td>
<td>IP</td>
<td>Open Label</td>
<td>50 mg per vial/ 1 vial per box</td>
<td>Store at 15° to 25°C.</td>
</tr>
</tbody>
</table>

<sup>a</sup> Labeled as either “BMS-936558-01” or “Nivolumab”

<sup>b</sup> For sites/countries in which investigative site staff will procure locally marketed product of topotecan and/or amrubicin, the potency/packaging size may differ based on the locally available product.
4.1 Investigational Product

An investigational product, also known as investigational medicinal product in some regions, is defined as a pharmaceutical form of an active substance or placebo being tested or used as a reference in a clinical study, including products already with a marketing authorization but used or assembled (formulated or packaged) differently than the authorized form, or used for an unauthorized indication, or when used to gain further information about the authorized form.

The investigational product should be stored in a secure area according to local regulations. It is the responsibility of the investigator to ensure that investigational product is only dispensed to study subjects. The investigational product must be dispensed only from official study sites by authorized personnel according to local regulations.

In this protocol, investigational product(s) are:

- Nivolumab
- Topotecan
- Amrubicin

4.1.1 Nivolumab

Nivolumab 240 mg (flat dose) on Day 1 of a 14-day cycle as an IV infusion over 30 minutes. Please refer to the current version of the Investigator Brochure and/or pharmacy reference sheets for complete storage, handling, preparation, and administration information for nivolumab.

4.1.2 Topotecan

Topotecan (subjects enrolled in the US, Europe, South America, Asia [except for Japan]): 1.5 mg/m$^2$ administered as 30-minute IV infusion once daily on Days 1 to 5 of a 21-day cycle. Please refer to the current version of the Summary of Product Characteristics (SmPC), US Package Insert (USPI), or other country-specific labeling and/or pharmacy reference sheet for complete storage, handling, preparation, and administration information for topotecan.

4.1.3 Amrubicin

Amrubicin (subjects enrolled in Japan): 40 mg/m$^2$ administered as 5-minute IV infusion once daily on Days 1 to 3 of a 21-day cycle. Please refer to the current version of the country-specific labeling and/or pharmacy reference sheet for complete storage, handling, preparation, and administration information for amrubicin.

4.2 Non-investigational Product

Other medications used as support or escape medication for preventative, diagnostic, or therapeutic reasons, as components of the standard of care for a given diagnosis, may be considered as non-investigational products.
In this protocol, non-investigational product(s) is/are: any pre-medications associated with the comparator arms and medications used to treat chemotherapy infusion-related reactions. Also, any medications used to treat nivolumab infusion-related reactions (e.g. steroids). These noninvestigational products should be sourced by the investigator sites if available and permitted by local regulations.

### 4.3 Storage and Dispensing

The product storage manager should ensure that the study drug is stored in accordance with the environmental conditions (temperature, light, and humidity) as determined by BMS. If concerns regarding the quality or appearance of the study drug arise, the study drug should not be dispensed and contact BMS immediately.

Study drug not supplied by BMS will be stored in accordance with the package insert.

Investigational product documentation (whether supplied by BMS or not) must be maintained that includes all processes required to ensure drug is accurately administered. This includes documentation of drug storage, administration and, as applicable, storage temperatures, reconstitution, and use of required processes (e.g., required diluents, administration sets).

### 4.4 Method of Assigning Subject Identification

#### 4.4.1 Screening

After informed consent has been obtained, the subject must be enrolled into the study by calling an interactive IVRS to obtain the subject number. The following information is required for subject registration:

- Date of birth
- Date of informed consent
- Gender.

#### 4.4.2 Randomization

Once a subject has been determined to meet eligibility criteria, site personnel will make another call to the IVRS. The following information is required for subject randomization:

- Subject number
- Confirmation that all randomization inclusion/exclusion are met
- Confirmation that FFPE tumor tissue block or unstained slides were received by the central laboratory
- Response to first-line platinum-based treatment: platinum sensitive vs platinum resistant
- Brain metastases at baseline: yes vs no.
If the above are met, the IVRS will randomly assign subjects to treatment Arm A or Arm B in a 1:1 ratio using a stratified permuted block randomization method with respect to the following stratification factors:

- Response to first-line platinum based treatment: platinum sensitive vs platinum resistant
- Brain metastases at baseline: yes vs no.

The first dose of study drug is to be administered within 3 days following randomization.

Randomization will be performed based on a randomization schedule generated and maintained by the Randomization Group within Bristol-Myers Squibb.

The procedures for using the IVRS will be detailed in a separate document.

### 4.5 Selection and Timing of Dose for Each Subject

#### 4.5.1 Dosing Schedule

The dosing schedule is detailed below Table 4.5.1-1.

<table>
<thead>
<tr>
<th>Table 4.5.1-1: Dosing Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arm A</strong></td>
</tr>
<tr>
<td>Nivolumab 240 mg a q 2 weeks</td>
</tr>
<tr>
<td>Day 1 Nivolumab</td>
</tr>
<tr>
<td>Day 1 Nivolumab</td>
</tr>
<tr>
<td>Day 1 Nivolumab</td>
</tr>
<tr>
<td><strong>Arm B</strong></td>
</tr>
<tr>
<td>Topotecan 1.5 mg/m² 1 – 5</td>
</tr>
<tr>
<td>Day 1 – 5 Topotecan</td>
</tr>
<tr>
<td>Day 1 - 5 Topotecan</td>
</tr>
<tr>
<td>Amrubicin 40 mg/m² 1 – 3</td>
</tr>
<tr>
<td>Day 1 – 3 Amrubicin</td>
</tr>
<tr>
<td>Day 1 - 3 Amrubicin</td>
</tr>
</tbody>
</table>

a Treatment continues until disease progression (or until discontinuation of study drug in subjects receiving nivolumab), discontinuation due to toxicity, withdrawal of consent, or the study ends.

All subjects will be monitored continuously for AEs while on study treatment. Treatment modifications (eg, dose delay, reduction, or discontinuation) will be based on specific laboratory and AE criteria, as described in Sections 4.5.2 and 4.5.3.
4.5.1.1 Nivolumab

For subjects randomized to Arm A, nivolumab will be administered as a flat dose of 240 mg on Day 1 of a 14-day cycle as an IV infusion over 30 minutes. The rationale for this dosage schedule is provided in Section 1.1.6.

Refer to the Pharmacy Information sheets for more detail. There are no pre-medications recommended on the first cycle. If an acute infusion reaction is noted, subjects should be managed according to Section 4.5.5.

Dosing Window: Subjects may be dosed no less than 12 days between doses and no more than 3 days from scheduled dose. If an infusion cannot be administered at a scheduled visit, it should be administered as soon as possible. Subsequent dosing visits will follow every 2 weeks after the delayed dose.

A dose given more than 3 days after the intended dose date will be considered a delay. A maximum delay of 6 weeks between doses is allowed.

Management Algorithms for Immuno-Oncology Agents

Immuno-oncology agents are associated with AEs that can differ in severity and duration than AEs caused by other therapeutic classes. Nivolumab is considered immuno-oncology agent in this protocol. Early recognition and management of AEs associated with immuno-oncology agents may mitigate severe toxicity. Management algorithms have been developed to assist investigators in assessing and managing the following groups of AEs:

- Gastrointestinal
- Renal
- Pulmonary
- Hepatic
- Endocrinopathies
- Skin
- Neurological.

The algorithms are found in the Investigator Brochure and Appendix 1 of this protocol.

Changes in tumor measurements and tumor responses will be assessed by the investigator using the RECIST 1.1 criteria. Please refer to Appendix 2 for the specifics of the RECIST 1.1 criteria to be utilized in this study.

4.5.1.2 Topotecan

Subjects randomized to Arm B (except Japan) will receive treatment with topotecan 1.5 mg/m$^2$ on Days 1 through 5 every 3 weeks (21 days). Refer to the local product label for more detail.

Dosing Window: Subjects may be dosed no less than 14 days from the last dose of the previous cycle and no more than 3 days from scheduled dose. If an infusion cannot be administered at a
scheduled visit, it should be administered as soon as possible. Subsequent dosing visits will follow every 3 weeks after the delayed dose.

A dose given more than 3 days after the intended dose date will be considered a delay. A maximum delay of 6 weeks between doses is allowed.

4.5.1.3 Amrubicin

Subjects randomized to Arm B (in Japan) will receive treatment with amrubicin 40 mg/m\(^2\) on Days 1 through 3 every 3 weeks (21 days). Refer to the local product label for more detail.

**Dosing Window:** Subjects may be dosed no less than 16 days from the last dose of the previous cycle and no more than 3 days from scheduled dose. If an infusion cannot be administered at a scheduled visit, it should be administered as soon as possible. Subsequent dosing visits will follow every 3 weeks after the delayed dose.

A dose given more than 3 days after the intended dose date will be considered a delay. A maximum delay of 6 weeks between doses is allowed.

4.5.2 Dose Modifications and Dose Delays

This section includes information on dose modifications, dose delays, and provides guidelines for resuming treatment after a dose delay. Tumor assessments for all subjects should continue as per protocol even if dosing is delayed.

4.5.2.1 Nivolumab

No dose modifications of nivolumab are allowed for the management of toxicities experienced by individual subjects.

Dose delay criteria apply for all drug-related AEs. Treatment delays up to 6 weeks (42 days) from the last dose are allowable.

Nivolumab administration should be delayed for the following:

- Any Grade \(\geq 2\) non-skin, drug-related AE, with the following exceptions:
  - Grade 2 drug-related fatigue or laboratory abnormalities do not require a treatment delay
- Any Grade 3 skin, drug-related AE
- Any Grade 3 drug-related laboratory abnormality, with the following exceptions for lymphopenia, leukopenia, AST, ALT, or total bilirubin:
  - Grade 3 lymphopenia or leukopenia does not require a dose delay.
  - If a subject has a baseline AST, ALT, or total bilirubin that is within normal limits, delay dosing for drug-related Grade \(\geq 2\) toxicity
  - If a subject has baseline AST, ALT, or total bilirubin within the Grade 1 toxicity range, delay dosing for drug-related Grade \(\geq 3\) toxicity
- Any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the investigator, warrants delaying the dose of study medication.
Criteria to Resume Treatment

Subjects may resume treatment with nivolumab when the drug-related AE(s) resolve to Grade ≤ 1 or baseline value, with the following exceptions:

- Subjects may resume treatment in the presence of Grade 2 fatigue
- Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in the presence of Grade 2 skin toxicity
- Subjects with baseline Grade 1 AST/ALT or total bilirubin who require dose delays for reasons other than a 2-grade shift in AST/ALT or total bilirubin may resume treatment in the presence of Grade 2 AST/ALT OR total bilirubin
- Subjects with combined Grade 2 AST/ALT AND total bilirubin values meeting discontinuation parameters ([Section 4.5.3.1](#)) should have treatment permanently discontinued
- Drug-related pulmonary toxicity, diarrhea, or colitis, must have resolved to baseline before treatment is resumed
- Drug-related endocrinopathies adequately controlled with only physiologic hormone replacement may resume treatment.

If the criteria to resume treatment are met, the subject should restart treatment at the next scheduled timepoint per protocol.

If treatment is delayed > 6 weeks (42 days) from the last dose, the subject must be permanently discontinued from study therapy, except as specified in Section 4.5.3.1.

4.5.2.2 Topotecan

Dose modifications and dose delays for the management of toxicities experienced by individual subjects in Arm B who are receiving topotecan are provided in Table 4.5.2.2-1. In addition, treatment may be delayed for any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the investigator, warrants delaying the dose of study medication.
Table 4.5.2.2-1: Topotecan Dose Modifications and Delays

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANC &lt; 1000/mm³ and/or Platelets &lt; 100,000/mm³ at Day 1</td>
<td>Delay treatment until: ANC &gt; 1000/mm³ Platelets &gt; 100,000/mm³</td>
</tr>
<tr>
<td>Toxicity Grade &lt; 2 during previous cycle</td>
<td>Optional, based on local treatment guidelines: Increase topotecan dosage to a maximum of 2 mg/m² per day in increments of 0.25 mg/m² per day.</td>
</tr>
<tr>
<td>Grade 4 neutropenia with fever or infection, or of duration ≥ 7 days</td>
<td>Reduce topotecan dosage by 0.25 mg/m² per day</td>
</tr>
<tr>
<td>Grade 3 neutropenia during the preceding cycle persisting after Day 21 Grade 4 thrombocytopenia</td>
<td>Reduce topotecan dosage by 0.25 mg/m² per day or discontinue treatment</td>
</tr>
<tr>
<td>Grade 3/4 Nonhematologic toxicity, excluding Grade 3 nausea</td>
<td></td>
</tr>
<tr>
<td>Treatment delay &gt; 6 weeks</td>
<td>Discontinue treatment</td>
</tr>
</tbody>
</table>

ANC = absolute neutrophil count

Note: the minimum permissible daily topotecan dosage is 1 mg/m²

Criteria to Resume Treatment

Subjects may resume treatment with topotecan when the drug-related AE(s) resolve to Grade ≤ 1 or baseline value, with the following exceptions:

- Treatment can be resumed when ANC > 1000/mm³ and platelets > 100,000/mm³
- Subjects may resume treatment in the presence of Grade 2 fatigue
- Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in the presence of Grade 2 skin toxicity
- Drug-related pulmonary toxicity must have resolved to baseline before treatment is resumed.

If the criteria to resume treatment are met, the subject should restart treatment at the next scheduled timepoint per protocol.

If treatment is delayed > 6 weeks (42 days) from the last dose, the subject must be permanently discontinued from study therapy, except as specified in Section 4.5.3.2.

When resuming topotecan treatment, please follow the dose reduction recommendations noted in Table 4.5.2.2-1.
4.5.2.3 Amrubicin

Dose modifications and dose delays for the management of toxicities experienced by individual subjects in Arm B who are receiving amrubicin are provided in Table 4.5.2.3-1. In addition, treatment may be delayed for any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the investigator, warrants delaying the dose of study medication.

Table 4.5.2.3-1: Amrubicin Dose Modifications

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANC &lt; 1000/mm³ and/or Platelets &lt; 100,000/mm³ at Day 1</td>
<td>Delay treatment until:</td>
</tr>
<tr>
<td></td>
<td>ANC ≥ 1000/mm³</td>
</tr>
<tr>
<td></td>
<td>Platelets ≥ 100,000/mm³</td>
</tr>
<tr>
<td>Grade 4 neutropenia with fever or infection, or of duration ≥ 7 days</td>
<td>Reduce amrubicin dosage by 5 mg/m² per day</td>
</tr>
<tr>
<td>Grade 3 neutropenia during the preceding cycle persisting after Day 21</td>
<td>Reduce amrubicin dosage by 5 mg/m² per day</td>
</tr>
<tr>
<td>Grade 4 thrombocytopenia</td>
<td></td>
</tr>
<tr>
<td>Grade 3/4 Nonhematologic toxicity, excluding Grade 3 nausea</td>
<td></td>
</tr>
<tr>
<td>Treatment delay &gt; 6 weeks</td>
<td>Discontinue treatment</td>
</tr>
</tbody>
</table>

ANC = absolute neutrophil count

Criteria to Resume Treatment

Subjects may resume treatment with amrubicin when the drug-related AE(s) resolve to Grade ≤ 1 or baseline value, with the following exceptions:

- Treatment can be resumed when WBC ≥ 1000/mm³, and platelets ≥ 100,000/mm³
- Subjects may resume treatment in the presence of Grade 2 fatigue
- Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in the presence of Grade 2 skin toxicity
- Drug-related pulmonary toxicity must have resolved to baseline before treatment is resumed.

If the criteria to resume treatment are met, the subject should restart treatment at the next scheduled timepoint per protocol.

If treatment is delayed > 6 weeks (42 days) from the last dose, the subject must be permanently discontinued from study therapy, except as specified in Section 4.5.3.3.
When resuming amrubicin treatment, please follow the dose reduction recommendations noted in Table 4.5.2.3-1.

### 4.5.3 Discontinuation Criteria

#### 4.5.3.1 Nivolumab

Treatment with nivolumab should be permanently discontinued for the following:

- Any Grade 2 drug-related uveitis or eye pain or blurred vision that does not respond to topical therapy and does not improve to Grade 1 severity within the re-treatment period OR requires systemic treatment
- Any Grade 3 non-skin, drug-related AE lasting > 7 days, with the following exceptions:
  - Grade 3 drug-related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, neurologic toxicity, hypersensitivity reaction, or infusion reaction of any duration requires discontinuation
  - Grade 3 drug-related laboratory abnormalities do not require treatment discontinuation except:
    - Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding requires discontinuation
    - Any drug-related liver function test (LFT) abnormality that meets the following criteria require discontinuation:
      - AST or ALT > 5-10x ULN for > 2 weeks
      - AST or ALT > 10x ULN
      - Total bilirubin > 5 x ULN
      - Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN
- Any Grade 4 drug-related AE or laboratory abnormality, except for the following events which do not require discontinuation:
  - Grade 4 neutropenia ≤ 7 days
  - Grade 4 lymphopenia or leukopenia
  - Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical sequelae and are corrected with supplementation/appropriate management within 72 hours of their onset
  - Grade 4 amylase or lipase abnormalities that are not associated with symptoms or clinical manifestations, or radiographic signs of pancreatitis. It is recommended to consult with the BMS Medical Monitor for Grade 4 amylase or lipase abnormalities.
  - For Grade 4 endocrinopathy AEs such as adrenal insufficiency, ACTH deficiency, hyper- or hypothyroidosis, or glucose intolerance, which resolve or are adequately controlled with physiologic hormone replacement (steroids, thyroid hormones) or glucose controlling agents, respectively, retreatment can be considered after discussion with the BMS Medical Monitor.
Any dosing interruption lasting > 6 weeks from the last dose with the following exceptions:

- Dosing interruptions to allow for prolonged steroid tapers to manage drug-related AEs are allowed. Prior to re-initiating treatment in a subject with a dosing interruption lasting > 6 weeks from the last dose, the BMS Medical Monitor must be consulted.
- Dosing interruptions > 6 weeks from the last dose that occur for non-drug-related reasons may be allowed if approved by the BMS Medical Monitor.

Any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the Investigator, presents a substantial clinical risk to the subject with continued nivolumab dosing.

Tumor assessments for all subjects should continue as per protocol even if study drug dosing is interrupted.

### 4.5.3.2 Topotecan

Treatment with topotecan should be permanently discontinued for the following:

- Confirmed new diagnosis of interstitial lung disease (ILD): Topotecan has been associated with reports of ILD, some of which have been fatal. Underlying risk factors include history of ILD, pulmonary fibrosis, lung cancer, thoracic exposure to radiation, and use of pneumotoxic drugs and/or colony stimulating factors. Monitor subjects for pulmonary symptoms indicative of interstitial lung disease (e.g., cough, fever, dyspnea, and/or hypoxia), and discontinue topotecan if a new diagnosis of ILD is confirmed.
- Any dosing interruption lasting > 6 weeks (42 days) from the last dose.
- Any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the Investigator, presents a substantial clinical risk to the subject with continued topotecan dosing.
- Any dosing interruption lasting > 6 weeks from the last dose with the following exception:
  - Dosing interruptions > 6 weeks from the last dose that occur for non-drug-related reasons may be allowed if approved by the BMS Medical Monitor.

### 4.5.3.3 Amrubicin

Treatment with amrubicin should be permanently discontinued for the following:

- Confirmed new diagnosis of interstitial lung disease (ILD): Amrubicin has been associated with reports of ILD, some of which have been fatal. Underlying risk factors include history of ILD, pulmonary fibrosis, lung cancer, thoracic exposure to radiation, and use of pneumotoxic drugs and/or colony stimulating factors. Monitor subjects for pulmonary symptoms indicative of interstitial lung disease (e.g., cough, fever, dyspnea, and/or hypoxia), and discontinue topotecan if a new diagnosis of ILD is confirmed.
- Any dosing interruption lasting > 6 weeks (42 days) from the last dose.

• Any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the Investigator, presents a substantial clinical risk to the subject with continued amrubicin dosing.

• Any dosing interruption lasting > 6 weeks from the last dose with the following exception:
  – Dosing interruptions > 6 weeks from the last dose that occur for non-drug-related reasons may be allowed if approved by the BMS Medical Monitor.

4.5.4  Treatment Beyond Disease Progression

Accumulating evidence indicates a minority of subjects treated with immunotherapy may derive clinical benefit despite initial evidence of PD.\textsuperscript{20}

Subjects in Arm B who were treated with topotecan or amrubicin will not be permitted to continue treatment beyond RECIST 1.1 defined initial PD.

Subjects in Arm A who were treated with Nivolumab will be permitted to continue treatment beyond initial RECIST 1.1 defined PD as long as they meet the following criteria:

• Investigator-assessed clinical benefit and no rapid disease progression
• Tolerating study drug
• Stable performance status
• Treatment beyond progression will not delay an imminent intervention to prevent serious complications of disease progression (eg, CNS metastases)
• Provides written informed consent prior to receiving additional nivolumab treatment, using an ICF describing any reasonably foreseeable risks or discomforts, or other alternative treatment options.

The assessment of clinical benefit should be balanced by clinical judgment as to whether the subject is clinically deteriorating and unlikely to receive any benefit from continued treatment with nivolumab.

All decisions to continue treatment beyond initial progression must be discussed with the BMS Medical Monitor and documented in the study records. The subject will continue to receive monitoring according to the Time and Events Schedule on Table 5.1-2.

A radiographic assessment/ scan should be performed within 6 weeks of original PD to determine whether there has been a decrease in the tumor size, or continued PD.

For the subjects who continue nivolumab study therapy beyond progression, further progression is defined as an additional 10% increase in tumor burden volume from time of initial PD. This includes an increase in the sum of all target lesions and/ or the development of new measurable lesions. For subjects with evaluable disease only, further progression is defined as unequivocal disease progression of non target lesions or the development of new measurable lesions from
time of initial PD. Treatment should be discontinued permanently upon documentation of further disease progression.

New lesions are considered measurable at the time of initial progression if the longest diameter is at least 10 mm (except for pathological lymph nodes, which must have a short axis of at least 15 mm). Any new lesion considered non-measurable at the time of initial progression may become measurable and therefore included in the tumor burden measurement if the longest diameter increases to at least 10 mm (except for pathological lymph nodes, which must have an increase in short axis to at least 15 mm).

For statistical analyses that include the investigator-assessed progression date, subjects who continue treatment beyond initial investigator-assessed, RECIST 1.1-defined progression will be considered to have investigator-assessed progressive disease at the time of the initial progression event.

For subjects in both treatment arms, global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as ‘symptomatic deterioration’. Every effort should be made to document objective progression (ie radiographic confirmation) even after discontinuation of treatment.

4.5.5 Treatment of Nivolumab-related Infusion Reactions

Since nivolumab contains only human immunoglobulin protein sequences, it is unlikely to be immunogenic and induce infusion or hypersensitivity reactions. However, if such a reaction were to occur, it might manifest with fever, chills, rigors, headache, rash, pruritus, arthralgias, hypo- or hypertension, bronchospasm, or other symptoms. All Grade 3 or 4 infusion reactions should be reported within 24 hours to the BMS Medical Monitor and reported as a serious adverse event (SAE) if criteria are met. Infusion reactions should be graded according to NCI CTCAE (version 4.0) guidelines.

Treatment recommendations are provided below and may be modified based on local treatment standards and guidelines as appropriate:

For Grade 1 symptoms: (Mild reaction; infusion interruption not indicated; intervention not indicated)

- Remain at bedside and monitor subject until recovery from symptoms. The following prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) at least 30 minutes before additional nivolumab administrations.

For Grade 2 symptoms: (Moderate reaction requires therapy or infusion interruption but responds promptly to symptomatic treatment [eg, antihistamines, non-steroidal anti inflammatory drugs, narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic medications indicated for ≤ 24 hours).
Stop the nivolumab infusion, begin an IV infusion of normal saline, and treat the subject with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen); remain at bedside and monitor subject until resolution of symptoms. Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the infusion is interrupted, then restart the infusion at 50% of the original infusion rate when symptoms resolve; if no further complications ensue after 30 minutes, the rate may be increased to 100% of the original infusion rate. Monitor subject closely. If symptoms recur then no further nivolumab will be administered at that visit. Administer diphenhydramine 50 mg IV, and remain at bedside and monitor the subject until resolution of symptoms. The amount of study drug infused must be recorded on the case report form (CRF).

The following prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) should be administered at least 30 minutes before additional nivolumab administrations. If necessary, corticosteroids (recommended dose: up to 25 mg of IV hydrocortisone or equivalent) may be used.

For Grade 3 or Grade 4 symptoms: (Severe reaction, Grade 3: prolonged [ie, not rapidly responsive to symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae [eg, renal impairment, pulmonary infiltrates]). Grade 4: (life threatening; pressor or ventilatory support indicated).

Immediately discontinue infusion of nivolumab. Begin an IV infusion of normal saline, and treat the subject as follows. Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 1:1,000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution injected slowly for IV administration, and/or diphenhydramine 50 mg IV with methylprednisolone 100 mg IV (or equivalent), as needed. Subject should be monitored until the investigator is comfortable that the symptoms will not recur. Nivolumab will be permanently discontinued. Investigators should follow their institutional guidelines for the treatment of anaphylaxis. Remain at bedside and monitor subject until recovery from symptoms.

In the case of late-occurring hypersensitivity symptoms (eg, appearance of a localized or generalized pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral antihistamine, or corticosteroids)

4.6 Blinding/Unblinding
Not applicable.

4.7 Treatment Compliance
Treatment compliance will be monitored by drug accountability as well as the subject’s medical record and CRF.
4.8 Destruction of Study Drug

For this study, study drugs (those supplied by BMS or sourced by the investigator) such as partially used study drug containers, vials and syringes may be destroyed on site.

Any unused study drugs can only be destroyed after being inspected and reconciled by the responsible Study Monitor unless study drug containers must be immediately destroyed as required for safety, or to meet local regulations (eg, cytotoxics or biologics).

On-site destruction is allowed provided the following minimal standards are met:

- On-site disposal practices must not expose humans to risks from the drug.
- On-site disposal practices and procedures are in agreement with applicable laws and regulations, including any special requirements for controlled or hazardous substances.
- Written procedures for on-site disposal are available and followed. The procedures must be filed with the site’s SOPs and a copy provided to BMS upon request.
- Records are maintained that allow for traceability of each container, including the date disposed of, quantity disposed, and identification of the person disposing the containers. The method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor must be documented.
- Accountability and disposal records are complete, up-to-date, and available for the Monitor to review throughout the clinical trial period.

If conditions for destruction cannot be met the responsible Study Monitor will make arrangements for return of study drug.

It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that procedures for proper disposal have been established according to applicable federal, state, local, and institutional guidelines and procedures, and provided that appropriate records of disposal are kept.

4.9 Return of Study Drug

If study drug will not be destroyed upon completion or termination of the study, all unused and/or partially used study drug that was supplied by BMS must be returned to BMS. The return of study drug will be arranged by the responsible Study Monitor.

It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that procedures for proper disposal have been established according to applicable federal, state, local, and institutional guidelines and procedures, and provided that appropriate records of disposal are kept.
### 5 STUDY ASSESSMENTS AND PROCEDURES

#### 5.1 Flow Chart/Time and Events Schedule

**Table 5.1-1: Screening Procedural Outline (CA209331)**

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Screening Visit</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eligibility Assessments</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>X</td>
<td>All inclusion/exclusion criteria should be assessed at screening and confirmed prior to first dose</td>
</tr>
<tr>
<td>Medical History</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Prior Systemic Therapy</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Safety Assessments</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Examination</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Physical Measurements</td>
<td>X</td>
<td>Include Height, Weight, and ECOG performance Status. Within 14 days prior to first dose</td>
</tr>
<tr>
<td>Vital Signs and Oxygen Saturation</td>
<td>X</td>
<td>Temperature, BP, HR, and O2 saturation by pulse oximetry at rest. Obtain vital signs at the screening visit and within 72 hours prior to first dose.</td>
</tr>
<tr>
<td>Assessment of Signs and Symptoms</td>
<td>X</td>
<td>Within 14 days prior to first dose</td>
</tr>
<tr>
<td>Laboratory Tests</td>
<td>X</td>
<td>CBC with differential, Chemistry panel including LDH, AST, ALT, ALP, T.Bili, BUN or serum urea level, uric acid, creatinine, Ca, Mg, Na, K, Cl, P, glucose, bicarbonate, albumin, amylose, lipase, TSH (reflex to free T3, free T4 for abnormal TSH result), hepatitis B surface antigen (HBVAg), and hepatitis C antibody (HCV Ab) or hepatitis C RNA (HCV RNA), within 14 days prior to first dose. Screening labs done within 72 hours prior to first dose can also be used for on treatment lab purposes at Day 1 dosing.</td>
</tr>
<tr>
<td>ECG, Echocardiogram (LEVF)</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>
Table 5.1-1: Screening Procedural Outline (CA209331)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Screening Visit</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy Test</td>
<td>X</td>
<td>Performed within 24 hours prior to first dose for WOCBP only (serum or urine - local/site)</td>
</tr>
<tr>
<td>Radiographic Tumor Assessment</td>
<td>X</td>
<td>Contrast-enhanced CT of the chest and CT or MRI of abdomen, pelvis, and any other known sites of disease. Brain MRI. Subjects with incidental brain metastases findings at screening will need to undergo radiation treatment first to be eligible. Should be performed within 28 days prior to first dose. Additional sites of known or suspected disease (including CNS) should be imaged at the screening visit and at subsequent on-study assessments.</td>
</tr>
<tr>
<td>IVRS/Clinical Drug Supplies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Calls to IVRS</td>
<td>X</td>
<td>Phone calls must be made to IVRS as follows: For subject number assignment at the time informed consent is obtained. For randomization to treatment after eligibility has been confirmed, or in the event of screen failure (subject does not meet eligibility criteria).</td>
</tr>
</tbody>
</table>

ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BP = blood pressure, BUN = blood urea nitrogen, Ca = calcium, CBC = complete blood count, Cl = chloride, CNS = central nervous system, CT = computed tomography, ECOG = Eastern Cooperative Oncology Group, HR = heart rate, IVRS = interactive voice response system, K = potassium, LDH = lactate dehydrogenase, Mg = magnesium, MRI = magnetic resonance imaging, Na = sodium, O2 = oxygen, P = phosphorus, T.Bili = total bilirubin, TSH = thyroid stimulating hormone, T3 = triiodothyronine, T4 = thyroxine, WOCBP = women of childbearing potential

* Within 28 days prior to first dose unless otherwise specified.
Table 5.1-2: On-Treatment Assessments for Subjects Randomized to Arm A, Nivolumab Monotherapy (CA209331)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Cycle 1 Day 1 (C1D1)</th>
<th>Cycle 1 Day 8 (C1D8)</th>
<th>Each Cycle (Every 2 Weeks) on Day 1 (± 3 Days)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety Assessments</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targeted Physical Examination</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>Within 72 hours prior to dosing</td>
</tr>
<tr>
<td>Vital Signs and Oxygen Saturation</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>Temperature, BP, HR, O2 saturation by pulse oximetry at rest (also monitor amount of supplemental oxygen if applicable) within 72 hours prior to dosing and at any time a subject has any new or worsening respiratory symptoms</td>
</tr>
<tr>
<td>Physical Measurements</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>Includes Weight and ECOG performance status</td>
</tr>
<tr>
<td>Adverse Events Assessment</td>
<td></td>
<td></td>
<td>-------- Continuous --------</td>
<td>Assessed using NCI CTCAE v. 4.0. SAEs should be approved in Trial Access Online (TAO) within 5 days from entry</td>
</tr>
<tr>
<td>Laboratory Tests</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>Extended on-study local laboratory assessments should be done within 72 hours prior to dosing for Cycle 1 through Cycle 5 and every alternate dose thereafter (Cycles 7, 9, 11, 13, etc.) and include: CBC with differential, uric acid, serum urea level, creatinine, Na, K, Ca, Mg, phosphorus, chloride, bicarbonate, amylase, lipase, glucose, AST, ALT, total bilirubin, alkaline phosphatase, LDH. Limited on-study local laboratory assessment should be done within 72 hours prior to dosing (beginning at Cycle 6 and every alternate dose thereafter (Cycles 8, 10, 12, 14, etc.) and include: CBC with differential, LFTs (ALT, AST, t.bili, alkaline phosphatase) and creatinine.</td>
</tr>
<tr>
<td>Thyroid Function Testing</td>
<td></td>
<td></td>
<td>See Note</td>
<td>TSH (reflex to free T3 and free T4 if abnormal result) to be performed every 6 weeks (± 1 week).</td>
</tr>
</tbody>
</table>
### Table 5.1-2: On-Treatment Assessments for Subjects Randomized to Arm A, Nivolumab Monotherapy (CA209331)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Cycle 1 Day 1 (C1D1)</th>
<th>Cycle 1 Day 8 (C1D8)</th>
<th>Each Cycle (Every 2 Weeks) on Day 1 (± 3 Days)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy Test</td>
<td>X</td>
<td></td>
<td>See Note</td>
<td>For WOCBP only: Serum or urine within 24 hours prior to first dose and then at least once every 4 weeks regardless of dosing schedule.</td>
</tr>
<tr>
<td>ECG, Echocardiogram (LEVF)</td>
<td></td>
<td></td>
<td>See Note</td>
<td>To be obtained at end of treatment only.</td>
</tr>
<tr>
<td><strong>Efficacy Assessments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Radiographic Tumor Assessment                  |                      |                      | See Note                                      | CT of the chest. CT/MRI of abdomen, pelvis, and any other known sites of disease. Subjects with a history of brain metastasis should have surveillance MRI every 6 weeks, or sooner if clinically indicated.  
The same methods should be used throughout the study.  See Table 5.4-1 for CT/MRI scan schedule. |
| **Pharmacokinetic (PK) and Immunogenicity Assessments** |                      |                      |                                               |                                                                                                                                                                                                |
| PK samples                                      | X                    |                      | See Note                                      | See Table 5.5-1 of PK and Immunogenicity Sampling                                                                                                                                              |
| Immunogenicity samples                          | X                    |                      | See Note                                      | See Table 5.5-1 of PK and Immunogenicity Sampling                                                                                                                                              |
### Table 5.1-2: On-Treatment Assessments for Subjects Randomized to Arm A, Nivolumab Monotherapy (CA209331)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Cycle 1 Day 1 (C1D1)</th>
<th>Cycle 1 Day 8 (C1D8)</th>
<th>Each Cycle (Every 2 Weeks) on Day 1 (± 3 Days)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outcomes Research Assessments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Reported Outcomes (PRO)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Health Resource Utilization</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study Drug</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administer Study Drug</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- For on-study visits: Assessments (Lung Cancer Symptom Scale and EQ-5D) will be performed prior to any study procedures and treatment.
- Assessments will be performed at each cycle on Day 1 for the first 6 months on study, then every 6 weeks thereafter for the remainder of the treatment phase.
- Except Cycle 1. Note that concomitant medication collection will be included.

ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BP = blood pressure, BUN = blood urea nitrogen, Ca = calcium, Cl = chloride, CNS = central nervous system, CT = computed tomography, ECG = electrocardiogram, ECOG = Eastern Cooperative Oncology Group, HR = heart rate, IVRS = interactive voice response system, K = potassium, LDH = lactate dehydrogenase, LFT = liver function tests, Mg = magnesium, MRI = magnetic resonance imaging, Na = sodium, NCI CTCAE = National Cancer Institute Common Toxicity Criteria for Adverse Events, O2 = oxygen, P = phosphorus, SAE = serious adverse event, T.Bili = total bilirubin, TSH = thyroid stimulating hormone, T3 = triiodothyronine, T4 = thyroxine, WOCBP = women of childbearing potential.

Date: 22-Apr-2015
Table 5.1-3: On-Treatment Assessments for Subjects Randomized to Arm B, Chemotherapy (CA209331)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Cycle 1 Day 1 of a 21-day Cycle (Every 3 Weeks ± 3 Days) (C1D1)</th>
<th>Cycle 2 to x Day 1 of a 21-day Cycle (Every 3 Weeks ± 3 Days) C2D1 to CxD1</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety Assessments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targeted Physical Examination</td>
<td>X</td>
<td>X</td>
<td>Within 72 hours prior to dosing</td>
</tr>
<tr>
<td>Vital Signs and Oxygen Saturation</td>
<td>X</td>
<td>X</td>
<td>Temperature, BP, HR, O2 saturation by pulse oximetry at rest (also monitor amount of supplemental oxygen if applicable) prior to dosing and at any time a subject has any new or worsening respiratory symptoms</td>
</tr>
<tr>
<td>Physical Measurements</td>
<td>X</td>
<td>X</td>
<td>Includes Weight and ECOG performance status</td>
</tr>
<tr>
<td>Adverse Events Assessment</td>
<td>---------------</td>
<td>Continuous ---------</td>
<td>Assessed using NCI CTCAE v. 4.0. SAEs should be approved in Trial Access Online (TAO) within 5 days from entry</td>
</tr>
<tr>
<td>Laboratory Tests</td>
<td>X (See Note)</td>
<td>X (See Note)</td>
<td>Extended on-study local laboratory assessments should be done within 72 hours prior to dosing and include: CBC with differential, uric acid, serum urea level, serum creatinine, sodium, potassium, calcium, magnesium, phosphorus, chloride, bicarbonate, amylase, lipase, glucose, AST, ALT, total bilirubin, alkaline phosphatase, LDH. In addition, the following laboratory assessments should be done: Day 15 of each cycle (optional according to local treatment guidelines): CBC with Differential, LFTs (ALT, AST, total bilirubin, alkaline phosphatase) and creatinine.</td>
</tr>
<tr>
<td>Thyroid Function Testing</td>
<td>See Note</td>
<td></td>
<td>TSH (reflex to free T3 and free T4 if abnormal result) to be performed every 6 weeks (± 1 week).</td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>X</td>
<td>See Note</td>
<td>For WOCBP only: Serum or urine within 24 hours prior to first dose and then at least once every 4 weeks regardless of dosing schedule.</td>
</tr>
<tr>
<td>ECG, Echocardiogram (LEVF)</td>
<td>See Note</td>
<td></td>
<td>To be obtained at end of treatment.</td>
</tr>
</tbody>
</table>

Date: 22-Apr-2015
Table 5.1-3: On-Treatment Assessments for Subjects Randomized to Arm B, Chemotherapy (CA209331)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Cycle 1 Day 1 of a 21-day Cycle (Every 3 Weeks ± 3 Days) (C1D1)</th>
<th>Cycle 2 to x Day 1 of a 21-day Cycle (Every 3 Weeks ± 3 Days) C2D1 to CxD1</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Efficacy Assessments</strong></td>
<td></td>
<td></td>
<td>CT of the chest. CT/MRI of abdomen, pelvis, and any other known sites of disease. Subjects with a history of brain metastasis should have surveillance by MRI every 6 weeks or sooner if clinically indicated. The same methods should be used throughout the study. See Table 5.4-1 for schedule of CT/MRI assessments.</td>
</tr>
<tr>
<td>Radiographic Tumor Assessment</td>
<td>See Note</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Outcomes Research Assessments</strong></td>
<td></td>
<td></td>
<td>For on-study visits: Assessments (Lung Cancer Symptom Scale and EQ-5D) will be performed prior to any study procedures and treatment. Assessments will be performed at each cycle on Day 1 for the first 6 months on study, then every 6 weeks thereafter for the remainder of the treatment period.</td>
</tr>
<tr>
<td>Patient Reported Outcomes (PRO)</td>
<td>X</td>
<td>See Note</td>
<td>Except Cycle 1. Note that concomitant medication collection will be included.</td>
</tr>
<tr>
<td>Health Resource Utilization</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 5.1-3: On-Treatment Assessments for Subjects Randomized to Arm B, Chemotherapy (CA209331)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Cycle 1 Day 1 of a 21-day Cycle (Every 3 Weeks ± 3 Days) (C1D1)</th>
<th>Cycle 2 to x Day 1 of a 21-day Cycle (Every 3 Weeks ± 3 Days) C2D1 to CxD1</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Drug</td>
<td>X (See Note)</td>
<td>X (See Note)</td>
<td>Topotecan (subjects enrolled in the US, Europe, South America, Asia [except for Japan]): 1.5 mg/m² administered as 30-minute IV infusion once daily on Days 1 to 5 of a 21-day cycle. Amrubicin (subjects enrolled in Japan): 40 mg/m² administered as 5-minute IV infusion once daily on Days 1 to 3 of a 21-day cycle. IVRS should be called within 1 day prior to study drug administration to receive vial assignment. Note: Treatment should begin within 3 business days of randomization. Subjects assigned to topotecan may be dosed no less than 14 days between doses and no more than 3 days from the scheduled dose. Subjects assigned to amrubicin may be dosed no less than 16 days between doses and no more than 3 days from the scheduled dose.</td>
</tr>
</tbody>
</table>

ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BP = blood pressure, BUN = blood urea nitrogen, Ca = calcium, Cl = chloride, CNS = central nervous system, CT = computed tomography, ECG = electrocardiogram, ECOG = Eastern Cooperative Oncology Group, HR = heart rate, IVRS = interactive voice response system, K = potassium, LDH = lactate dehydrogenase, LFT = liver function tests, Mg = magnesium, MRI = magnetic resonance imaging, Na = sodium, NCI CTCAE = National Cancer Institute Common Toxicity Criteria for Adverse Events, O2 = oxygen, P = phosphorus, SAE = serious adverse event, T.Bili = total bilirubin, TSH = thyroid stimulating hormone, T3 = triiodothyronine, T4 = thyroxine, WOCBP = women of childbearing potential
### Table 5.1-4: Follow-Up Assessments for All Treatment Groups (CA209331)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>X, Follow-Up Visits 1 and 2&lt;sup&gt;a&lt;/sup&gt;</th>
<th>S, Survival Follow-Up Visits&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety Assessments</strong></td>
<td></td>
<td></td>
<td>To assess for potential late emergent study drug related issues</td>
</tr>
<tr>
<td>Targeted Physical Examination</td>
<td>X</td>
<td></td>
<td>Non-SAEs and SAEs must be collected up to 100 days after study drug discontinuation. SAEs that relate to any later protocol specified procedure must be collected. SAEs should be approved in Trial Access Online (TAO) within 5 days from entry.</td>
</tr>
<tr>
<td>Adverse Events Assessment</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Laboratory Tests</td>
<td>X</td>
<td></td>
<td>CBC with differential, uric acid, BUN, serum creatinine, Na, K, Ca, Mg, Cl, P, bicarbonate, glucose, AST, ALT, t.bili, ALP, LDH.</td>
</tr>
<tr>
<td>Thyroid Function Testing</td>
<td>X</td>
<td></td>
<td>TSH (reflex to free T3 and free T4 if abnormal result)</td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>X</td>
<td></td>
<td>Serum or urine</td>
</tr>
<tr>
<td>ECG, Echocardiogram (LEVF)</td>
<td>X</td>
<td></td>
<td>Only at Follow-up Visit 1</td>
</tr>
<tr>
<td><strong>Efficacy Assessments</strong></td>
<td></td>
<td></td>
<td>See Table 5.4-1 for schedule of CT/MRI assessments. For subjects without previous disease progression only.</td>
</tr>
<tr>
<td>Radiographic Tumor Assessment</td>
<td>See Note</td>
<td>See note</td>
<td>See Table 5.4-1 for schedule of CT/MRI assessments. For subjects without previous disease progression only.</td>
</tr>
<tr>
<td><strong>Pharmacokinetic and Immunogenicity Assessments</strong></td>
<td></td>
<td></td>
<td>See Table 5.5-1 of PK and Immunogenicity Sampling. For subjects randomized to nivolumab monotherapy only.</td>
</tr>
<tr>
<td>PK Samples</td>
<td>X</td>
<td></td>
<td>See Table 5.5-1 of PK and Immunogenicity Sampling. For subjects randomized to nivolumab monotherapy only.</td>
</tr>
</tbody>
</table>
Table 5.1-4: Follow-Up Assessments for All Treatment Groups (CA209331)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>X, Follow-Up Visits 1 and 2&lt;sup&gt;a&lt;/sup&gt;</th>
<th>S, Survival Follow-Up Visits&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunogenicity samples</td>
<td>X</td>
<td></td>
<td>See Table 5.5-1 of PK and Immunogenicity Sampling. For subjects randomized to nivolumab monotherapy only.</td>
</tr>
<tr>
<td>Outcomes Research Assessments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Reported Outcomes (PRO)</td>
<td>X</td>
<td>EQ-5D only</td>
<td>Both the Lung Cancer Symptom Scale and EQ-5D will be given in Follow-up Visits 1 &amp; 2. In Survival Visits, EQ-5D is collected every 3 months for the first year of the Follow-up Phase, then every 6 months thereafter.</td>
</tr>
<tr>
<td>Subject Status</td>
<td></td>
<td>X</td>
<td>Every 3 months after X02; may be accomplished by visit or phone contact, to update survival information and assess subsequent anti-cancer therapy.</td>
</tr>
</tbody>
</table>

ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BP = blood pressure, BUN = blood urea nitrogen, Ca = calcium, Cl = chloride, CT = computed tomography, ECG = electrocardiogram, IVRS = interactive voice response system, K = potassium, LDH = lactate dehydrogenase, Mg = magnesium, MRI = magnetic resonance imaging, Na = sodium, NCI CTCAE = National Cancer Institute Common Toxicity Criteria for Adverse Events, O2 = oxygen, P = phosphorus, SAE = serious adverse event, T.Bili = total bilirubin, TSH = thyroid stimulating hormone, T3 = triiodothyronine, T4 = thyroxine, WOCBP = women of childbearing potential

<sup>a</sup> Follow-up visits occur as follows: X01 = 35 days (± 7 days) from last dose, X02 = 80 days (± 7 days) from X01

<sup>b</sup> S, Survival visits continue every 3 months (± 7 days) after Follow-up Visit 2 until death, lost to follow-up, or withdrawal of study consent
5.1.1 Retesting During Screening or Lead-in Period

Retesting of laboratory parameters and/or other assessments within any single Screening or Lead-in period will be permitted (in addition to any parameters that require a confirmatory value).

5.2 Study Materials

The following materials will be provided to the site by BMS.

- NCI CTCAE version 4.0
- Nivolumab Investigator Brochure
- Pharmacy Binder
- Laboratory manuals for collection and handling of blood (including biomarker and immunogenicity) and tissue specimens
- Site manual for operation of interactive voice response system, including enrollment worksheets
- Manual for entry of local laboratory data
- Pregnancy Surveillance Forms
- Serious Adverse Events (or eSAE) case report forms
- Lung Cancer Symptom Score and EuroPRO Group’s EQ-5D questionnaires
- RECIST 1.1 pocket guide.

5.3 Safety Assessments

Safety assessments include AEs, physical examinations, vital signs, ECOG performance status, assessment of signs and symptoms, laboratory tests, pregnancy tests as outlined in Section 5.1.

5.3.1 Imaging Assessment for the Study

Any incidental findings of potential clinical relevance that are not directly associated with the objectives of the protocol should be evaluated and handled by the Study Investigator as per standard medical/clinical judgment.

5.4 Efficacy Assessments

Study evaluations will take place in accordance with the flow charts in Section 5.1. Baseline assessments should be performed within 28 days of randomization.

Contrast-enhanced computed tomography (CT) of the chest and CT or magnetic resonance imaging (MRI) of abdomen, pelvis, and any other known sites of disease are the preferred methods of radiographic assessment of tumors. Brain MRI scan is the preferred imaging method for evaluating CNS metastasis, and assessment is required at screening. Subjects with incidental brain metastases findings at screening will need to undergo radiation treatment first to be eligible. If a subject has a known allergy to contrast material, please use local prophylaxis.
standards to obtain the assessment with contrast if at all possible, or use the alternate modality. In cases where contrast is strictly contraindicated, a non-contrast scan will suffice.

All known or suspected sites of disease (including CNS) should be assessed at screening and at subsequent assessments using the same imaging method and technique. If more than one method is used at screening, then the most accurate method according to RECIST 1.1 should be used when recording data, and should again be used for all subsequent assessments.

Bone scan, PET scan, or ultrasound are not adequate for assessment of RECIST 1.1 response. In selected circumstances where such modalities are the sole modality used to assess certain non-target organs, those non target organs may be evaluated less frequently. For example, bone scans may need to be repeated only when complete response is identified in target disease or when progression in bone is suspected.

Previously treated CNS metastases are not considered measurable lesions for purposes of RECIST 1.1 response. Subjects with a history of brain metastasis should have surveillance MRI approximately every 6 weeks, or sooner if clinically indicated.

Subjects will be evaluated for tumor response beginning 6 weeks from the date of first dose (±5 days), then every 6 weeks (±5 days) thereafter up to 30 weeks, then it will be every 12 weeks (±5 days) until disease progression (or until discontinuation of study drug in subjects receiving nivolumab beyond progression), lost to follow-up, withdrawal of study consent, or the study ends. See Table 5.4-1 for a schedule of tumor assessments. Tumor assessments for all subjects should continue as per protocol even if dosing is delayed. Tumor measurements should be made by the same investigator or radiologist for each assessment whenever possible.

Tumor imaging assessments for ongoing study treatment decisions will be completed by the investigator using RECIST 1.1 criteria; see Appendix 2.

Table 5.4-1: Schedule of CT/MRI Tumor Assessments

<table>
<thead>
<tr>
<th>Time On Study</th>
<th>Assessment Frequency</th>
<th>Assessment Week (Day 1 of Week Shown)</th>
<th>Assessment Window</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td></td>
<td>Week 0</td>
<td>– 28 days</td>
</tr>
<tr>
<td>Between Week 6 and Week 30</td>
<td>Every 6 weeks</td>
<td>6, 12, 18, 24, 30</td>
<td>± 5 days</td>
</tr>
<tr>
<td>Beyond Week 30</td>
<td>Every 12 weeks</td>
<td>42, 54, 66+</td>
<td>± 5 days</td>
</tr>
</tbody>
</table>

Note: Tumor assessments will continue until disease progression (or until discontinuation of study drug in subjects receiving nivolumab beyond progression), lost to follow-up, withdrawal of study consent, or the study ends.

5.4.1 Primary Efficacy Assessment

The primary endpoint is OS in all randomized subjects. See Section 8.3.1 for the definition of OS. Every effort will be made to collect survival data on all subjects including subjects withdrawn from treatment for any reason, who are eligible to participate in the study and who have not withdrawn consent for survival data collection. If the death of a subject is not reported,
all dates in this study representing a date of subject contact will be used in determination of the subject’s last known date alive.

### 5.4.2 Secondary Efficacy Assessment

Key secondary endpoints include PFS and ORR, based on investigator assessment using RECIST 1.1 criteria.

Subjects achieving a timepoint response of CR or PR will require confirmation for BOR determination as per RECIST 1.1, according to the protocol defined tumor assessment schedule. In the case of SD, measurements must have met the SD criteria at least once after study entry at a minimum interval of 6 weeks (± 5 days).

The investigator assessed ORR will be further characterized by the investigator-determined DOR and time to response (TTR).

See Section 8.3.2 for further details.

### 5.5 Pharmacokinetic and Immunogenicity Assessments

PK and immunogenicity samples will be collected according to the schedule listed in Table 5.5-1 for all subjects treated with nivolumab and analyzed by validated assays.

All on-treatment PK timepoints are intended to align with days on which nivolumab is administered. If it is known that a dose is going to be delayed, then the predose sample should be collected just prior to the delayed dose. However, if a predose sample is collected, but the dose is subsequently delayed, an additional predose sample should not be collected. Separate, detailed instructions for the collection, processing, handling, labeling, storage, and shipment of PK and immunogenicity samples will be provided in the central lab manual.
Table 5.5-1: Pharmacokinetics and Immunogenicity Sampling Schedule (Nivolumab) (CA209331)

<table>
<thead>
<tr>
<th>Study Day</th>
<th>Time (Relative to Dosing) Hour</th>
<th>Time (Relative to Dosing) Hour: Min</th>
<th>Nivolumab PK Blood Sample</th>
<th>Nivolumab Immunogenicity Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1 Day 1</td>
<td>predose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>00:00</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Cycle 3 Day 1</td>
<td>predose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>00:00</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Cycle 11 Day 1</td>
<td>predose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>00:00</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Cycle 19 Day 1</td>
<td>predose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>00:00</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Cycle 27 Day 1</td>
<td>predose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>00:00</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Cycle 39 Day 1</td>
<td>predose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>00:00</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Day 1 of every 12th cycle from Cycle 39 until discontinuation of study drug</td>
<td>predose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>00:00</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>First 2 Follow-up visits- FU1 &amp; FU2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PK - pharmacokinetics

<sup>a</sup> Predose samples should be taken just prior to the administration (preferably within 30 minutes).

<sup>b</sup> If a subject permanently discontinues study drug treatment during the sampling period, they will move to sampling at follow-up visits
5.7 Outcomes Research Assessments

The evaluation of health related quality of life is an increasingly important aspect of a clinical efficacy. Such data provides an understanding of the impact of treatment from the subjects’ perspective and offers insights into the patient experience that may not be captured through physician reporting. Generic health related quality of life scales additionally provide data necessary in calculating utility values for health economic models. The EQ-5D will be collected in order to assess the impact of study treatment on generic health related quality of life, which will also be used in populating health economic models most notably, cost effectiveness analysis.

The LCSS will be collected to assess the impact of study treatment on patient reported disease related symptoms. The LCSS is a validated instrument designed to assess the impact of treatment on disease-related symptoms. It consists of 6 symptom specific questions related to dyspnea, cough, fatigue, pain, hemoptysis and anorexia plus 3 summary items: symptom distress, interference with activity, and global health related quality of life (HRQoL). The degree of impairment is recorded on a 100 mm visual analogue scale with scores from 0 to 100 with zero representing the best score.

General health status will be measured using the EQ-5D. The EQ-5D is a standardized instrument for use as a measure of self-reported health status. The EQ-5D comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety) and a visual analog rating scale (VAS). The utility data generated from the EQ-5D is recommended for and commonly used in cost effectiveness analysis.

Healthcare resource utilization data (eg, hospitalizations, non-protocol specified medical visits, etc) will be collected for all randomized subjects. Specifically, healthcare resource utilization is
evaluated based on the number of medical care encounters such as hospital admissions and their
duration, outpatient visits, diagnostic tests and procedures, concomitant medications and reasons
for the encounters.

5.8 Other Assessments

5.8.1 Immunogenicity Assessments

Serum samples collected at timepoints identified in Table 5.5-1 will be analyzed by a validated
immunogenicity assay. As part of the immunogenicity assessment, samples may also be analyzed
for neutralizing antibodies by a validated method. All on-treatment immunogenicity timepoints
are intended to align with days on which nivolumab is administered. If a predose sample is
collected, but the dose is subsequently delayed, an additional predose sample should not be
collected. If it is known that a dose is going to be delayed, then the predose sample should be
collected just prior to the delayed dose. Selected serum samples may be analyzed by an
exploratory method that measures anti-nivolumab antibodies for technology exploration
purposes.

In addition, serum samples designated for PK or biomarker assessments may also be used for
immunogenicity analysis if required (eg, insufficient volume for complete immunogenicity
assessment or to follow up on suspected immunogenicity related AE).

6 ADVERSE EVENTS

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a
preexisting medical condition in a clinical investigation subject administered study drug and that
does not necessarily have a causal relationship with this treatment. An AE can therefore be any
unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease
temporally associated with the use of study drug, whether or not considered related to the study
drug.

The causal relationship to study drug is determined by a physician and should be used to assess
all adverse events (AE). The causal relationship can be one of the following:

- Related: There is a reasonable causal relationship between study drug administration and
  the AE.

- Not related: There is not a reasonable causal relationship between study drug
  administration and the AE.

The term "reasonable causal relationship" means there is evidence to suggest a causal
relationship.

Adverse events can be spontaneously reported or elicited during open-ended questioning,
examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be
questioned regarding the specific occurrence of one or more AEs.)
6.1 Serious Adverse Events

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:

- results in death
- is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)
- requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE below)
- results in persistent or significant disability/incapacity
- is a congenital anomaly/birth defect
- is an important medical event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the subject or may require intervention [eg, medical, surgical] to prevent one of the other serious outcomes listed in the definition above.) Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization.) Potential drug induced liver injury (DILI) is also considered an important medical event. (See Section 6.6 for the definition of potential DILI.)

Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the study drug is an SAE.

Although pregnancy, overdose, cancer, and potential drug induced liver injury (DILI) are not always serious by regulatory definition, these events must be handled as SAEs. (See Section 6.1.1 for reporting pregnancies).

Any component of a study endpoint that is considered related to study drug (eg, death is an endpoint, if death occurred due to anaphylaxis, anaphylaxis must be reported) should be reported as SAE (see Section 6.1.1 for reporting details).

NOTE:

The following hospitalizations are not considered SAEs in BMS clinical studies:

- a visit to the emergency room or other hospital department < 24 hours, that does not result in admission (unless considered an important medical or life-threatening event)
- elective surgery, planned prior to signing consent
- admissions as per protocol for a planned medical/surgical procedure
- routine health assessment requiring admission for baseline/trending of health status (eg, routine colonoscopy)
- medical/surgical admission other than to remedy ill health and planned prior to entry into the study. Appropriate documentation is required in these cases.
– admission encountered for another life circumstance that carries no bearing on health status and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, caregiver respite, family circumstances, administrative reason).
– Admission for administration of anticancer therapy in the absence of any other SAEs (applies to oncology protocols).

6.1.1 ** Serious Adverse Event Collection and Reporting**

Sections 5.6.1 and 5.6.2 in the Investigator Brochure represent the Reference Safety Information to determine expectedness of serious adverse events for expedited reporting. Following the subject’s written consent to participate in the study, all SAEs, whether related or not related to study drug, must be collected, including those thought to be associated with protocol-specified procedures. All SAEs must be collected that occur during the screening period and within 100 days of discontinuation of dosing. If applicable, SAEs must be collected that relate to any later protocol-specified procedure (e.g., a follow-up skin biopsy).

The investigator should report any SAE that occurs after these time periods and that is believed to be related to study drug or protocol-specified procedure.

An SAE report should be completed for any event where doubt exists regarding its seriousness.

If the investigator believes that an SAE is not related to study drug, but is potentially related to the conditions of the study (such as withdrawal of previous therapy or a complication of a study procedure), the relationship should be specified in the narrative section of the SAE Report Form.

SAEs, whether related or not related to study drug, and pregnancies must be reported to BMS (or designee) within 24 hours of awareness of the event. SAEs must be recorded on the SAE Report Form; pregnancies on a Pregnancy Surveillance Form (electronic or paper forms). The preferred method for SAE data reporting collection is through the CRF. The paper SAE/pregnancy surveillance forms are only intended as a back-up option when the electronic CRF system is not functioning. In this case, the paper forms are to be transmitted via email or confirmed facsimile (fax) transmission to:

**SAE Email Address:** Refer to Contact Information list.

**SAE Facsimile Number:** Refer to Contact Information list.

For studies capturing SAEs through electronic data capture (EDC), electronic submission is the required method for reporting. The paper forms should be used and submitted immediately, only in the event the electronic system is unavailable for transmission. When paper forms are used, the original paper forms are to remain on site.

**SAE Telephone Contact** (required for SAE and pregnancy reporting): Refer to Contact Information list.

If only limited information is initially available, follow-up reports are required. (Note: Follow-up SAE reports should include the same investigator term(s) initially reported.)
If an ongoing SAE changes in its intensity or relationship to study drug or if new information becomes available, a follow-up SAE report should be sent within 24 hours to the BMS (or designee) using the same procedure used for transmitting the initial SAE report. All SAEs should be followed to resolution or stabilization.

6.2 Nonserious Adverse Events

A nonserious adverse event is an AE not classified as serious.

6.2.1 Nonserious Adverse Event Collection and Reporting

The collection of nonserious AE information should begin at initiation of study drug. Nonserious AE information should also be collected from the start of a placebo lead-in period or other observational period intended to establish a baseline status for the subjects.

Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they become serious (see Section 6.1.1). Follow-up is also required for nonserious AEs that cause interruption or discontinuation of study drug and for those present at the end of study treatment as appropriate. All identified nonserious AEs must be recorded and described on the nonserious AE page of the CRF (paper or electronic).

All nonserious AEs (not only those deemed to be treatment-related) should be collected continuously during the treatment period and for a minimum of 100 days following the last dose of study treatment.

Completion of supplemental CRFs may be requested for AEs and/or laboratory abnormalities that are reported/identified during the course of the study.

6.3 Laboratory Test Result Abnormalities

The following laboratory test result abnormalities should be captured on the nonserious AE CRF page or SAE Report Form (paper or electronic) as appropriate:

- Any laboratory test result that is clinically significant or meets the definition of an SAE
- Any laboratory test result abnormality that required the subject to have study drug discontinued or interrupted
- Any laboratory test result abnormality that required the subject to receive specific corrective therapy.

It is expected that wherever possible, the clinical rather than laboratory term would be used by the reporting investigator (eg, anemia versus low hemoglobin value).

6.4 Pregnancy

If, following initiation of the study drug, it is subsequently discovered that a study subject is pregnant or may have been pregnant at the time of study exposure, including during at least 5 half lives after product administration, the investigator must immediately notify the BMS.
Medical Monitor/designee of this event and complete and forward a Pregnancy Surveillance Form to BMS Designee within 24 hours of awareness of the event and in accordance with SAE reporting procedures described in Section 6.1.1.

In most cases, the study drug will be permanently discontinued in an appropriate manner (eg, dose tapering if necessary for subject safety).

In the rare event that the benefit of continuing study drug is thought to outweigh the risk, after consultation with BMS, the pregnant subject may continue study drug after a thorough discussion of benefits and risk with the subject.

The investigator must immediately notify the BMS (or designee) Medical Monitor of this event and complete and forward a Pregnancy Surveillance Form to BMS (or designee) within 24 hours of awareness of the event and in accordance with SAE reporting procedures described in Section 6.1.1.

Follow-up information regarding the course of the pregnancy, including perinatal and neonatal outcome and, where applicable, offspring information must be reported on the Pregnancy Surveillance Form.

Any pregnancy that occurs in a female partner of a male study participant should be reported to BMS. Information on this pregnancy will be collected on the Pregnancy Surveillance Form.

6.5 Overdose

An overdose is defined as the accidental or intentional administration of any dose of a product that is considered both excessive and medically important. All occurrences of overdose must be reported as an SAE (see Section 6.1.1 for reporting details.).

6.6 Potential Drug Induced Liver Injury (DILI)

Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting the defined criteria, must be reported as SAEs (see Section 6.1.1 for reporting details).

Potential drug induced liver injury is defined when all three of the following are present:

1) Aminotransaminase (AT, ALT or AST) elevation > 3 times upper limit of normal (ULN)
2) Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline phosphatase),
3) No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the administration of other drug(s) known to be hepatotoxic.

6.7 Other Safety Considerations

Any significant worsening noted during interim or final physical examinations, electrocardiogram, x-ray filming, any other potential safety assessment required or not required
by protocol should also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.

7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL COMMITTEES

One independent committee will be utilized, a DMC. The DMC will be utilized to provide general oversight and safety considerations for this study, CA209331. The DMC will provide advice to the Sponsor regarding actions the committee deems necessary for the continuing protection of subjects enrolled in this study. The DMC will be charged with assessing such actions in light of an acceptable risk/benefit profile for nivolumab. The DMC will act in an advisory capacity to BMS and will monitor subject safety data for the study.

The DMC will be advisory to the clinical study leadership team. The clinical study leadership will have responsibility for overall conduct of the study including managing the communication of study data. The group will be responsible for promptly reviewing the DMC recommendations, for providing guidance regarding the continuation or termination of the study, and for determining whether amendments to the protocol or changes to the study conduct are required.

Details of the DMC responsibilities and procedures will be specified in the DMC charter.

When required, adjudicated events will be submitted to the DMC and Health Authorities for review on a specified timeframe in accordance with the adjudication documentation.

8 STATISTICAL CONSIDERATIONS

8.1 Sample Size Determination

In this study, the primary endpoint of OS will be evaluated for treatment effect at the overall alpha level of 0.05 (two-sided) with 90% power, accounting for one formal interim analysis to assess efficacy. Approximately 480 subjects will be randomized at a ratio of 1:1 into two arms: Arm A (nivolumab); Arm B (chemotherapy – ie, topotecan or amrubicin [Japan only]).

The study requires at least 338 deaths to ensure that a two-sided 5% significance level sequential test procedure with one interim analysis will have 90% power to detect a HR of 0.7, corresponding to a median OS of 8 vs 11.4 months for the chemotherapy and nivolumab monotherapy treatment arms, respectively.

The formal comparison of OS at interim will allow for early stopping for superiority, and the boundaries for declaring superiority will be derived based on the actual number of deaths using Lan-DeMets α spending function with O’Brien and Fleming type of boundary in EAST v5.4. If the analysis is performed exactly at 237 deaths (70% of the expected number of events at the final analysis), the boundary for declaring superiority would be 0.0148 (or 0.73 with regard to HR boundary, which corresponds to about 3 months improvement in median OS under the assumed control arm hazard function). The boundary for declaring superiority for the final analysis after 338 events would be 0.0455. This would correspond to an observed hazard ratio of 0.8 or less would lead to a statistically significant result; which can be translated to a 2-month
improvement in terms of median OS, using same median control assumption. The cumulative power up to interim and final OS analysis will be 61.5% and 90% respectively.

The secondary endpoints PFS and ORR will be tested hierarchically (see Section 8.4.2).

Assuming a median PFS on chemotherapy and nivolumab are 3.5 months and 5 months (HR = 0.7) respectively. At the time of interim analysis of OS, it is expected that there will be approximately 371 PFS events. This will provide more than 90% power to detect difference of 1.5 months in median PFS. In addition, approximately 443 PFS events will occur at the time of the final analysis of OS. This gives more than 95% power to detect a treatment difference of 1.5 months with an overall two-sided type 1 error of 0.05.

### Table 8.1-1: Key Parameters of Overall Survival Analysis

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Timing</th>
<th>Largest Observed HR for significance</th>
<th>Probability for declaring superiority Under H1/H0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy arm: median OS = 8 months</td>
<td>Interim analysis for superiority</td>
<td>237 deaths at 15 months (11 months accrual ± 4 months of follow-up)</td>
<td>0.73 (P &lt; 0.015)</td>
</tr>
<tr>
<td>Nivolumab arm: median OS = 11.4 months (HR = 0.7)</td>
<td>Final analysis for superiority</td>
<td>338 deaths at 22.5 months (11 months of accrual + 11.5 months of follow-up)</td>
<td>0.82 (P &lt; 0.046)</td>
</tr>
</tbody>
</table>

Total probability to declare superiority Under H1/H0: 90% / 5%

### 8.2 Populations for Analyses

- All enrolled subjects: All subjects who sign an informed consent form and are registered into the IVRS.
- All randomized subjects: All subjects who are randomized to any treatment arm in the study. This is the primary dataset for analyses of efficacy and baseline characteristics.
- All treated subjects: All subjects who received at least one dose of nivolumab, or chemotherapy. This is the primary dataset for dosing and safety.
- PK subjects: All subjects with available serum time-concentration data from randomized subjects dosed with nivolumab.
- All PD-L1 tested subjects: All subjects, randomized or not, who had a tumor biopsy specimen available for PD-L1 expression testing (validated assay). This includes both randomized and screen failure subjects.
• All randomized subjects with quantifiable PD-L1 expression at baseline: Randomized subjects with at least one tumor sample collected at baseline, with number viable tumor cells \( \geq 100 \), and percentage of viable tumor cells exhibiting PD-L1 membrane staining \( \geq 0\% \).

8.3 Endpoints

8.3.1 Primary Endpoint(s)
The primary endpoint for the study is OS. It is defined as the time from randomization to the date of death. A subject who has not died will be censored at last known date alive. OS will be followed continuously while subjects are on the study drug and every 3 months via in-person or phone contact after subjects discontinue the study drug.

8.3.2 Secondary Endpoint(s)
Secondary endpoints include ORR and PFS.

8.3.2.1 Progression Free Survival
PFS is defined as the time from randomization to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Subjects who die without a reported prior progression will be considered to have progressed on the date of their death. Subjects who did not progress or die will be censored on the date of their last evaluable tumor assessment. Subjects who did not have any on study tumor assessments and did not die will be censored on the date they were randomized. Subjects who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the last evaluable tumor assessment prior to initiation of the subsequent anti-cancer therapy. Tumor response will be assessed every 6 weeks (± 5 days) (from the first dose of study drug) until Week 30, and every 12 weeks (± 5 days). Tumor assessment will continue until disease progression (or until discontinuation of study drug in subjects receiving nivolumab beyond progression), lost to follow-up, withdrawal of study consent, or the study ends.

8.3.2.2 Objective Response Rate
The ORR will be based on the best overall response on study defined using RECIST 1.1, as assessed by the investigator. ORR is defined as the proportion of all randomized subjects whose BOR from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best response between the date of randomization and the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. For subjects without documented progression or subsequent anti-cancer therapy, all available response designations will contribute to the BOR determination. For subjects who continue nivolumab beyond progression, the BOR should be determined based on tumor assessments before initial RECIST 1.1 defined progression. The comparison of ORR will be carried out using a two-sided Cochran-Mantel-Haenszel (CMH) test stratified by the stratification factors as described in
Section 3.1 associated odds ratio and 95% CI will be calculated. Rates and their 2-sided exact CI will be calculated by the method of Clopper and Pearson for each randomized arm.

In addition, DOR and TTR will be summarized in each randomized arm. DOR is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Subjects who neither progress nor die will be censored on the date of their last assessment. TTR is defined as the time from randomization to the date of the first confirmed CR or PR. DOR and TTR will be evaluated for responders (confirmed CR or PR) only.
8.4 Analyses

8.4.1 Demographics and Baseline Characteristics

Demographics and baseline laboratory results will be summarized by treatment arm as randomized using descriptive statistics for all randomized subjects.

8.4.2 Efficacy Analyses

All hypothesis testing will be two-sided based on a significance level of 0.05 except for OS. A group sequential testing procedure will be applied to OS to control the overall type I error for interim and final analyses. The $\alpha$ spending function is described in Section 8.1. If superiority of OS is demonstrated, a hierarchical hypothesis testing approach for the key secondary endpoints will be used to preserve a study-wise type I error rate at 0.05. The key secondary endpoints will be tested in the following hierarchical order:

1) PFS
2) ORR.

The formal statistical testing for PFS will take place only if OS is statistically significant and the statistical testing for ORR will take place only if both OS and PFS are statistically significant.

8.4.2.1 Methods of Primary Endpoint

The distribution of OS will be compared in two randomized arms at the interim and final looks via a two-sided, log-rank test stratified by the stratification factors as described in Section 3.1. The HR and the corresponding two-sided 100x (1-adjusted $\alpha$)% CI will be estimated in a stratified Cox proportional hazards model using randomized arm as a single covariate. The OS curves for each randomized arm will be estimated using the Kaplan-Meier (KM) product-limit method. Two-sided, 95% confidence intervals for median OS will be computed by Brookmeyer and Crowley method. Survival rates at 6, 12, 18, 24, 36, 48 months and 5 years will be estimated using KM estimates on the OS curve for each randomized arm provided minimum follow-up is longer than timepoint to generate the rate. Associated two-sided 95% CIs will be calculated using the Greenwood formula.

8.4.2.2 Methods for Secondary Endpoint

The distribution of PFS will be compared in two randomized arms using a two-sided, log-rank test stratified by the stratification factors as described in Section 3.1. The HR and the corresponding two-sided 95% CI will be estimated in a stratified Cox proportional hazards model using randomized arm as a single covariate. The PFS curves for each randomized arm will be estimated using the KM product-limit method. Two-sided, 95% confidence intervals for median PFS will be computed by Brookmeyer and Crowley method.

ORR in two randomized arms will be compared using a two-sided CMH test, stratified by the same factors. An associated odds ratio and 95% CI will also be calculated. Rates and their
The corresponding 95% exact CI will be calculated by Clopper-Pearson method for each randomized arm.

The estimation of DOR and TTR in two randomized arms will be computed for subjects who achieve PR or CR using KM product-limit method. Median values of duration and time-to, along with two-sided 95% CI, will be calculated.

### 8.4.3 Safety Analyses

The safety analysis will be performed in all treated subjects. Descriptive statistics of safety will be presented using NCI CTCAE version 4.0 by treatment arm. All on-treatment AEs, drug-related AEs, late-emergent drug-related AEs, SAEs and drug-related SAEs will be tabulated using worst grade per NCI CTCAE version 4.0 criteria by system organ class and preferred term. On-study lab parameters including hematology, coagulation, chemistry, liver function and renal function will be summarized using worst grade per NCI CTCAE v 4.0 criteria.

### 8.4.4 Pharmacokinetic Analyses

The concentration vs time data obtained in this study may be combined with data from other studies in the clinical development program to develop a population PK model. This model may be used to evaluate the effects of intrinsic and extrinsic covariates on the PK of nivolumab and to determine measures of individual exposure (such as steady-state peak, trough, and time-averaged concentration). Model determined exposures may be used for exposure-response analyses of selected efficacy and safety end points. Results of population PK and exposure-response analyses will be reported separately.
8.4.6 Outcomes Research Analyses

LCSS questionnaire complete rate, defined as the proportion of questionnaires actually received out of the expected number (ie, the number of subjects still on treatment in follow-up), will be calculated and summarized at each assessment point.

Baseline and change from baseline of the average symptom burden index score at each assessment point will be summarized using descriptive statistics.

Subject’s overall health state on a visual analog scale (EQ-VAS) at each assessment time point will be summarized using descriptive statistics Proportion of subjects reporting problems for the 5 EQ-5D dimensions at each assessment time point will be summarized by level of problem.

Summary statistics will be calculated for the population preference-based health state utility score (EQ-5D Index).
8.5 Interim Analyses

A formal interim analysis for the OS is planned after at least 237 deaths have been observed, which are expected to occur approximately 15 months after study initiation. This formal comparison of OS will allow for early stopping for superiority. Lan-DeMets $\alpha$ spending function with O’Brien and Fleming type of boundary will be used. The stopping boundary will depend on the actual number of deaths at the time of the interim analysis. However, if the analysis were performed exactly at 237 deaths, the study could be stopped by the DMC for superiority if the p-value is < 0.0148. An independent statistician from external to BMS will perform the analysis. If the study continues beyond the interim analysis the nominal significance level for the final look after 403 deaths would be 0.0455. All events in the database at the time of the lock will be used. If number of final events exceeds the number specified per protocol (338 deaths), final boundary will not be recalculated using updated information fraction at interim.

In addition to the formal planned interim analysis for OS, the DMC will have access to periodic unblinded interim reports of efficacy and safety to allow a risk/benefit assessment. No formal test will be performed and the study will not stop for superiority. Details will be included in the DMC charter.

9 STUDY MANAGEMENT

9.1 Compliance

9.1.1 Compliance with the Protocol and Protocol Revisions

The study shall be conducted as described in this approved protocol. All revisions to the protocol must be discussed with, and be prepared by, BMS. The investigator should not implement any deviation or change to the protocol without prior review and documented approval/favorable opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate hazard(s) to study subjects.

If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to obtaining IRB/IEC approval/favorable opinion, as soon as possible the deviation or change will be submitted to:

- IRB/IEC for review and approval/favorable opinion
- BMS
- Regulatory Authority(ies), if required by local regulations

Documentation of approval signed by the chairperson or designee of the IRB(s)/IEC(s) must be sent to BMS.
If an amendment substantially alters the study design or increases the potential risk to the subject: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects currently enrolled in the study if they are affected by the amendment; and (3) the new form must be used to obtain consent from new subjects prior to enrollment.

If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).

### 9.1.2 Monitoring

BMS representatives will review data centrally to identify potential issues to determine a schedule of on-site visits for targeted review of study records.

Representatives of BMS must be allowed to visit all study site locations periodically to assess the data quality and study integrity. On site they will review study records and directly compare them with source documents, discuss the conduct of the study with the investigator, and verify that the facilities remain acceptable.

In addition, the study may be evaluated by BMS internal auditors and government inspectors who must be allowed access to CRFs, source documents, other study files, and study facilities. BMS audit reports will be kept confidential.

The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, and promptly forward copies of inspection reports to BMS.

#### 9.1.2.1 Source Documentation

The Investigator is responsible for ensuring that the source data are accurate, legible, contemporaneous, original and attributable, whether the data are hand-written on paper or entered electronically. If source data are created (first entered), modified, maintained, archived, retrieved, or transmitted electronically via computerized systems (and/or any other kind of electronic devices) as part of regulated clinical trial activities, such systems must be compliant with all applicable laws and regulations governing use of electronic records and/or electronic signatures. Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), AE tracking/reporting, protocol required assessments, and/or drug accountability records.

When paper records from such systems are used in place of electronic format to perform regulated activities, such paper records should be certified copies. A certified copy consists of a copy of original information that has been verified, as indicated by a dated signature, as an exact copy having all of the same attributes and information as the original.

### 9.1.3 Investigational Site Training

Bristol-Myers Squibb will provide quality investigational staff training prior to study initiation. Training topics will include but are not limited to: GCP, AE reporting, study details and procedure, electronic CRFs, study documentation, informed consent, and enrollment of WOCBP.
9.2 Records

9.2.1 Records Retention

The investigator must retain all study records and source documents for the maximum period required by applicable regulations and guidelines, or institution procedures, or for the period specified by BMS, whichever is longer. The investigator must contact BMS prior to destroying any records associated with the study.

BMS will notify the investigator when the study records are no longer needed.

If the investigator withdraws from the study (e.g., relocation, retirement), the records shall be transferred to a mutually agreed upon designee (e.g., another investigator, IRB). Notice of such transfer will be given in writing to BMS.

9.2.2 Study Drug Records

It is the responsibility of the investigator to ensure that a current disposition record of study drug (inventoried and dispensed) is maintained at the study site to include investigational product. Records or logs must comply with applicable regulations and guidelines and should include:

- amount received and placed in storage area
- amount currently in storage area
- label identification number or batch number
- amount dispensed to and returned by each subject, including unique subject identifiers
- amount transferred to another area/site for dispensing or storage
- nonstudy disposition (e.g., lost, wasted)
- amount destroyed at study site, if applicable
- amount returned to BMS
- retain samples for bioavailability/bioequivalence, if applicable
- dates and initials of person responsible for Investigational Product dispensing/accountability, as per the Delegation of Authority Form.

BMS will provide forms to facilitate inventory control if the investigational site does not have an established system that meets these requirements.
9.2.3 Case Report Forms

An investigator is required to prepare and maintain adequate and accurate case histories designed to record all observations and other data pertinent to the investigation on each individual treated or entered as a control in the investigation. Data that are derived from source documents and reported on the CRF must be consistent with the source documents or the discrepancies must be explained. Additional clinical information may be collected and analyzed in an effort to enhance understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities that are reported or identified during the course of the study.

For sites using the BMS electronic data capture tool, electronic CRFs will be prepared for all data collection fields except for fields specific to SAEs and pregnancy, which will be reported on the paper or electronic SAE form and Pregnancy Surveillance form, respectively. Spaces may be left blank only in those circumstances permitted by study-specific CRF completion guidelines provided by BMS.

The confidentiality of records that could identify subjects must be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirement(s).

The investigator will maintain a signature sheet to document signatures and initials of all persons authorized to make entries and/or corrections on CRFs.

The completed CRF, including any paper or electronic SAE/pregnancy CRFs, must be promptly reviewed, signed, and dated by the investigator or qualified physician who is a subinvestigator and who is delegated this task on the Delegation of Authority Form. For electronic CRFs, review and approval/signature is completed electronically through the BMS electronic data capture tool. The investigator must retain a copy of the CRFs including records of the changes and corrections.

Each individual electronically signing electronic CRFs must meet BMS training requirements and must only access the BMS electronic data capture tool using the unique user account provided by BMS. User accounts are not to be shared or reassigned to other individuals.

9.3 Clinical Study Report and Publications

A Signatory Investigator must be selected to sign the clinical study report.

For this protocol, the Signatory Investigator will be selected as appropriate based on the following criteria:

- External Principal Investigator designated at protocol development
- National Coordinating Investigator
- Study Steering Committee chair or their designee
- Subject recruitment (eg, among the top quartile of enrollers)
- Involvement in trial design
• Regional representation (eg, among top quartile of enrollers from a specified region or country)
• Other criteria (as determined by the study team).

The data collected during this study are confidential and proprietary to BMS. Any publications or abstracts arising from this study must adhere to the publication requirements set forth in the clinical trial agreement (CTA) governing [Study site or Investigator] participation in the study. These requirements include, but are not limited to, submitting proposed publications to BMS at the earliest practicable time prior to submission or presentation and otherwise within the time period set forth in the CTA.
10 **GLOSSARY OF TERMS**

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete Abstinence</td>
<td>If one form of contraception is required, Complete Abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs. Female subjects must continue to have pregnancy tests. Acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence. If two forms of contraception is required, Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs. Subjects who choose complete abstinence are not required to use a second method of contraception, but female subjects must continue to have pregnancy tests. Acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence. <strong>Expanded definition</strong> Complete abstinence as defined as complete avoidance of heterosexual intercourse is an acceptable form of contraception for all study drugs. This also means that abstinence is the preferred and usual lifestyle of the subject. This does not mean periodic abstinence (e.g., calendar, ovulation, symptothermal, profession of abstinence for entry into a clinical trial, post-ovulation methods) and withdrawal, which are not acceptable methods of contraception. Subjects who choose complete abstinence are not required to use a second method of contraception, but female subjects must continue to have pregnancy tests. Acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence.</td>
</tr>
</tbody>
</table>
## LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>ANC</td>
<td>absolute neutrophil count</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AT</td>
<td>aminotransaminases</td>
</tr>
<tr>
<td>BOR</td>
<td>best overall response</td>
</tr>
<tr>
<td>BMS</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>BUN</td>
<td>blood urea nitrogen</td>
</tr>
<tr>
<td>C</td>
<td>Celsius</td>
</tr>
<tr>
<td>Ca</td>
<td>calcium</td>
</tr>
<tr>
<td>CAV</td>
<td>cyclophosphamide, doxorubicin, vincristine</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CMH</td>
<td>Cochran-Mantel-Haenszel</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form, paper or electronic</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTA</td>
<td>clinical trial agreement</td>
</tr>
<tr>
<td>DILI</td>
<td>drug-induced liver disease</td>
</tr>
<tr>
<td>DMC</td>
<td>data monitoring committee</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of objective response</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>EDC</td>
<td>electronic data capture</td>
</tr>
<tr>
<td>ED-SCLC</td>
<td>Extensive Stage Disease</td>
</tr>
<tr>
<td>eg</td>
<td>exempli gratia (for example)</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FFPE</td>
<td>formalin-fixed, paraffin-embedded</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle stimulating hormone</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>HR</td>
<td>heart rate</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>HRQoL</td>
<td>health related quality of life</td>
</tr>
<tr>
<td>HRT</td>
<td>hormone replacement therapy</td>
</tr>
<tr>
<td>ICD</td>
<td>International Classification of Diseases</td>
</tr>
<tr>
<td>ICF</td>
<td>informed consent form</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>ie</td>
<td>id est (that is)</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committee</td>
</tr>
<tr>
<td>IHC</td>
<td>immunohistochemistry</td>
</tr>
<tr>
<td>ILD</td>
<td>interstitial lung disease</td>
</tr>
<tr>
<td>IMP</td>
<td>investigational medicinal products</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug Exemption</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>ITIM</td>
<td>immunoreceptor tyrosine inhibitory motif</td>
</tr>
<tr>
<td>ITSM</td>
<td>immunoreceptro tyrosine-based switch motif</td>
</tr>
<tr>
<td>IU</td>
<td>International Unit</td>
</tr>
<tr>
<td>IUD</td>
<td>intrauterine device</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous(ly)</td>
</tr>
<tr>
<td>IVRS</td>
<td>interactive voice response system</td>
</tr>
<tr>
<td>K</td>
<td>potassium</td>
</tr>
<tr>
<td>KM</td>
<td>Kaplan-Meier</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>LCSS</td>
<td>Lung Cancer Symptom Scale</td>
</tr>
<tr>
<td>LDH</td>
<td>lactate dehydrogenase</td>
</tr>
<tr>
<td>LD-SCLC</td>
<td>Limited Stage Disease</td>
</tr>
<tr>
<td>mAbs</td>
<td>monoclonal antibodies</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>N</td>
<td>number of subjects or observations</td>
</tr>
<tr>
<td>Na</td>
<td>sodium</td>
</tr>
<tr>
<td>N/A</td>
<td>not applicable</td>
</tr>
<tr>
<td>NCCN</td>
<td>National Comprehensive Cancer Network</td>
</tr>
<tr>
<td>NCI CTCAE</td>
<td>National Cancer Institute Common Toxicity Criteria for Adverse Events</td>
</tr>
<tr>
<td>NIMP</td>
<td>non-investigational medicinal products</td>
</tr>
<tr>
<td>NSCLC</td>
<td>non-small cell lung cancer</td>
</tr>
<tr>
<td>ORR</td>
<td>objective response rate</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>PBMC</td>
<td>peripheral blood mononuclear cell</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PD-1</td>
<td>Programmed death receptor-1</td>
</tr>
<tr>
<td>PFS</td>
<td>progression free survival</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetics</td>
</tr>
<tr>
<td>PO</td>
<td>per os (by mouth route of administration)</td>
</tr>
<tr>
<td>Pop PK</td>
<td>Population PK</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>Q2W</td>
<td>every 2 weeks</td>
</tr>
<tr>
<td>RCC</td>
<td>renal cell carcinoma</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SCLC</td>
<td>small-cell lung cancer</td>
</tr>
<tr>
<td>SD</td>
<td>stable disease</td>
</tr>
<tr>
<td>SNP</td>
<td>single nucleotide polymorphism</td>
</tr>
<tr>
<td>TAO</td>
<td>Trial Access Online, the BMS implementation of an EDC capability</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>TCR</td>
<td>T-cell receptor</td>
</tr>
<tr>
<td>TTR</td>
<td>time to response</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>VAS</td>
<td>visual analogue scale</td>
</tr>
<tr>
<td>WBC</td>
<td>white blood cell</td>
</tr>
<tr>
<td>WOCBP</td>
<td>women of childbearing potential</td>
</tr>
</tbody>
</table>
APPENDIX 1 MANAGEMENT ALGORITHMS

These general guidelines constitute guidance to the Investigator and may be supplemented by discussions with the Medical Monitor representing the Sponsor. The guidance applies to all immuno-oncology (I-O) agents and regimens. A general principle is that differential diagnoses should be diligently evaluated according to standard medical practice. Non-inflammatory etiologies should be considered and appropriately treated.

Corticosteroids are a primary therapy for immuno-oncology drug-related adverse events. The oral equivalent of the recommended IV doses may be considered for ambulatory patients with low-grade toxicity. The lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids. Consultation with a medical or surgical specialist, especially prior to an invasive diagnostic or therapeutic procedure, is recommended.

The frequency and severity of the related adverse events covered by these algorithms will depend on the immuno-oncology agent or regimen being used.
GI Adverse Event Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause is identified, treat accordingly and continue I-O therapy. Opiates/narcotics may mask symptoms of perforation. Infliximab should not be used in cases of perforation or sepsis.

### Grade of Diarrhea/Colitis (NCI CTCAE v4)

#### Grade 1
- Diarrhea: < 4 stools/day over baseline; Colitis: asymptomatic
- Continue I-O therapy per protocol
- Symptomatic treatment

#### Grade 2
- Diarrhea: 4-6 stools per day over baseline; IV fluids indicated <24 hours (hrs); not interfering with ADL
- Colitis: abdominal pain; blood in stool
- Delay I-O therapy per protocol
- Symptomatic treatment

#### Grade 3-4
- Diarrhea (G3): ≥ 7 stools per day over baseline; incontinence; IV fluids ≥ 24 hrs; interfering with activities of daily living (ADL)
- Colitis (G3): severe abdominal pain, medical intervention indicated, peritoneal signs
- G4: life-threatening, perforation
- Discontinue I-O therapy per protocol
- 1.0 to 2.0 mg/kg/day methylprednisolone IV or IV equivalent
- Add prophylactic antibiotics for opportunistic infections
- Consider lower endoscopy

### Management

- Close monitoring for worsening symptoms.
- Educate patient to report worsening immediately
  - If worsens:
    - Treat as Grade (G) 2 or 3/4

### Follow-up

- If improves to grade 1:
  - Resume I-O therapy per protocol
  - If persists > 5-7 days or recur:
    - 0.5-1.0 mg/kg/day methylprednisolone or oral equivalent
    - When symptoms improve to grade 1, taper steroids over at least 1 month, consider prophylactic antibiotics for opportunistic infections, and resume I-O therapy per protocol.
  - If worsens or persists > 3-5 days with oral steroids:
    - Treat as grade 3/4

- If improves:
  - Continue steroids until grade 1, then taper over at least 1 month
  - If persists > 3-5 days, or recurs after improvement:
    - Add infliximab 5 mg/kg (if no contraindication).
    - Note: Infliximab should not be used in cases of perforation or sepsis

Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g., prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.
Renal Adverse Event Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy.

**Grade of Creatinine Elevation (NCI CTC v4)**

**Grade 1**
Creatinine > upper limit of normal (ULN) and > 1.5x baseline
- Continue I-O therapy per protocol
- Monitor creatinine weekly

**Grade 2-3**
Creatinine > 1.5x baseline to ≤ 6x ULN
- Delay I-O therapy per protocol
- Monitor creatinine every 2-3 days
- 0.5 to 1.0 mg/kg/day methylprednisolone IV or oral equivalent
- Consider renal biopsy

**Grade 4**
Creatinine > 6x ULN
- Discontinue I-O therapy per protocol
- Monitor creatinine daily
- 1.0-2.0 mg/kg/day methylprednisolone IV or IV equivalent
- Consult nephrologist
- Consider renal biopsy

**Management**

**Follow-up**

If returns to baseline:
- Resume routine creatinine monitoring per protocol
If worsens:
- Treat as Grade 2 or 3/4

If returns to Grade 1:
- Taper steroids over at least 1 month, consider prophylactic antibiotics for opportunistic infections, and resume I-O therapy and routine creatinine monitoring per protocol
If elevations persist > 7 days or worsen:
- Treat as Grade 4

If returns to Grade 1: Taper steroids over at least 1 month and add prophylactic antibiotics for opportunistic infections

Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.

Date: 22-Apr-2015

Approved v1.0  930089510 1.0
Pulmonary Adverse Event Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy. Evaluate with imaging and pulmonary consultation.

**Grade of Pneumonitis (NCI CTCAE v4)**

**Grade 1**
Radiographic changes only

**Grade 2**
Mild to moderate new symptoms

**Grade 3-4**
Severe new symptoms; New/worsening hypoxia; Life-threatening

**Management**

- Consider delay of I-O therapy
- Monitor for symptoms every 2-3 days
- Consider Pulmonary and Infectious Disease (ID) consults

- Delay I-O therapy per protocol
- Pulmonary and ID consults
- Monitor symptoms daily, consider hospitalization
- 1.0 mg/kg/day methylprednisolone IV or oral equivalent
- Consider bronchoscopy, lung biopsy

- Discontinue I-O therapy per protocol
- Hospitalize
- Pulmonary and ID consults
- 2-4 mg/kg/day methylprednisolone IV or IV equivalent
- Add prophylactic antibiotics for opportunistic infections
- Consider bronchoscopy, lung biopsy

**Follow-up**

- Re-image at least every 3 weeks
  If worsens:
  - Treat as Grade 2 or 3-4

- Re-image every 1-3 days
  If improves:
  - When symptoms return to near baseline, taper steroids over at least 1 month and then resume I-O therapy per protocol and consider prophylactic antibiotics
  If not improving after 2 weeks or worsening:
  - Treat as Grade 3-4

- If improves to baseline:
  - Taper steroids over at least 6 weeks
  If not improving after 48 hours or worsening:
  - Add additional immunosuppression (e.g. infliximab, cyclophosphamide, intravenous immunoglobulin (IVIG), or mycophenolate mofetil)

Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.
Hepatic Adverse Event Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy. Consider imaging for obstruction.

### Grade of Liver Test Elevation

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>AST or ALT &gt; ULN to 3.0 x ULN and/or Total bilirubin (T. billi) &gt; ULN - 1.5 x ULN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 2</td>
<td>AST or ALT &gt; 3.0 to ≤ 5 x ULN and/or T. billi &gt; 1.5 to ≤ 3 x ULN</td>
</tr>
<tr>
<td>Grade 3-4</td>
<td>AST or ALT &gt; 5 x ULN and/or T. billi &gt; 3 x ULN</td>
</tr>
</tbody>
</table>

### Management

- **Grade 1**: Continue I-O therapy per protocol
- **Grade 2**: Delay I-O therapy per protocol. Increase frequency of monitoring to every 3 days.
- **Grade 3-4**: Discontinue I-O therapy. Increase frequency of monitoring to every 1-2 days. 1.0 to 2.0 mg/kg/day methylprednisolone IV or IV equivalent. Add prophylactic antibiotics for opportunistic infections. Consult gastroenterologist.

### Follow-up

- **Grade 1**: Continue liver function tests (LFT) monitoring per protocol if worsens: Treat as Grade 2 or 3-4.
- **Grade 2**: If returns to baseline: Resume routine monitoring, resume I-O therapy per protocol if elevations persist > 5-7 days or worsen:
  - 0.5-1 mg/kg/day methylprednisolone or oral equivalent and when LFT returns to grade 1 or baseline, taper steroids over at least 1 month, consider prophylactic antibiotics for opportunistic infections, and resume I-O therapy per protocol.
- **Grade 3-4**: If returns to grade 2:
  - Taper steroids over at least 1 month
  - If does not improve in >3-5 days, worsens or rebounds:
    - Add mycophenolate mofetil 1 gram (g) twice daily (BID)
    - If no response within an additional 3-5 days, consider other immunosuppressants per local guidelines

---

Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.

*I-O therapy may be delayed rather than discontinued if AST/ALT ≤ 8 x ULN and T. billi ≤ 5 x ULN.*

**The recommended starting dose for grade 4 hepatitis is 2 mg/kg/day methylprednisolone IV.**
Endocrinopathy Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy. Consider visual field testing, endocrinology consultation, and imaging.

Asymptomatic thyroid stimulating hormone (TSH) elevation

- Continue I-O therapy per protocol
- If TSH < 0.5 x lower limit of normal (LLN), or TSH > 2 x ULN, or consistently out of range in 2 subsequent measurements: include free thyroxine (fT4) at subsequent cycles as clinically indicated; consider endocrinology consult

Symptomatic endocrinopathy

- Evaluate endocrine function
- Consider pituitary scan

Symptomatic with abnormal lab/pituitary scan:
- Delay I-O therapy per protocol
- 1-2 mg/kg/day methylprednisolone IV or by mouth (PO) equivalent
- Initiate appropriate hormone therapy

No abnormal lab/pituitary MRI scan but symptoms persist:
- Repeat labs in 1-3 weeks /MRI in 1 month

If improves (with or without hormone replacement):
- Taper steroids over at least 1 month and consider prophylactic antibiotics for opportunistic infections
- Resume I-O therapy per protocol
- Patients with adrenal insufficiency may need to continue steroids with mineralocorticoid component

Suspicion of adrenal crisis (e.g. severe dehydration, hypotension, shock out of proportion to current illness)

- Delay or discontinue I-O therapy per protocol
- Rule out sepsis
- Stress dose of IV steroids with mineralocorticoid activity
- IV fluids
- Consult endocrinologist
- If adrenal crisis ruled out, then treat as above for symptomatic endocrinopathy

Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.
Skin Adverse Event Management Algorithm
Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy.

**Grade of Rash**
(NTC CTCAE v4) 

**Grade 1-2**
Covering ≤ 30% body surface area (BSA)*
- Symptomatic therapy (e.g. antihistamines, topical steroids)
- Continue I-O therapy per protocol

**Grade 3-4**
Covering >30% BSA; Life threatening consequences*
- Delay or discontinue I-O therapy per protocol
- Consider skin biopsy
- Dermatology consult
- 1.0-2.0 mg/kg/day IV methylprednisolone IV or IV equivalent

**Management**

**Follow-up**
- If persists > 1-2 weeks or recurs:
  - Consider skin biopsy
  - Delay I-O therapy per protocol
  - Consider 0.5-1.0 mg/kg/day methylprednisolone IV or oral equivalent. Once improving, taper steroids over at least 1 month, consider prophylactic antibiotics for opportunistic infections, and resume I-O therapy per protocol
- If worsens:
  - Treat as Grade 3-4

- If improves to Grade 1:
  - Taper steroids over at least 1 month and add prophylactic antibiotics for opportunistic infections
  - Resume I-O therapy per protocol

Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.

*Refer to NCI CTCAE v4 for term-specific grading criteria.
Neurological Adverse Event Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy.

**Grade of Neurological Toxicity (NCI CTCAE v4)**

**Grade 1**
Asymptomatic or mild symptoms; intervention not indicated

**Management**
- Continue I-O therapy per protocol

**Follow-up**
- Continue to monitor the patient.
  - If worsens:
    - Treat as Grade 2 or 3-4

**Grade 2**
Moderate symptoms; limiting instrumental ADL

- Delay I-O therapy per protocol
- Treat symptoms per local guidelines
- Consider 0.5 to 1.0 mg/kg/day methylprednisolone IV or PO equivalent

**Follow-up**
- If improves to baseline:
  - Resume I-O therapy per protocol when improved to baseline
  - If worsens:
    - Treat as Grade 3-4

**Grade 3-4**
Severe symptoms; limiting self-care ADL; life-threatening

- Discontinue I-O therapy per protocol
- Obtain neurology consult
- Treat symptoms per local guidelines
  - 1.0-2.0 mg/kg/day IV methylprednisolone IV or IV equivalent
  - Add prophylactic antibiotics for opportunistic infections

**Follow-up**
- If improves to Grade 2:
  - Taper steroids over at least 1 month
- If worsens or atypical presentation:
  - Consider IVIG or other immunosuppressive therapies per local guidelines

Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.
APPENDIX 2    RECIST 1.1

1    ASSESSMENT OF OVERALL TUMOR BURDEN AND MEASURABLE DISEASE

To assess objective response or future progression, it is necessary to estimate the overall tumor burden at baseline and use this as a comparator for subsequent measurements. Measurable disease is defined by the presence of at least one measurable tumor lesion. When CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.

At baseline, tumor lesions/lymph nodes will be categorized measurable or non-measurable as follows:

1.1    Measurable Lesions

Measurable lesions must be accurately measured in at least one dimension (longest diameter in the plane of the measurement to be recorded) with a minimum size of:

- 10 mm by CT/MRI scan - (CT/MRI scan slice thickness no greater than 5 mm)
- 20 mm by chest x-ray
- Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node must be ≥15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis will be measured and followed.

1.2    Non-measurable Lesions

- All other lesions, including small lesions (longest diameter < 10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), as well as truly non-measurable lesions.
- Lesions considered truly non-measurable include: leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly identified by physical exam that is not measurable by reproducible imaging techniques.

1.3    Special Considerations Regarding Lesion Measurability

1.3.1    Bone Lesions

- Bone scan, PET scan or plain films are not considered adequate imaging techniques to measure bone lesions. However, these techniques can be used to confirm the presence or disappearance of bone lesions.
• Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, that can be evaluated by cross sectional imaging techniques such as CT or MRI can be considered as measurable lesions if the soft tissue component meets the definition of measurability described above.

• Blastic bone lesions are non-measurable.

1.3.2 Cystic Lesions

• Lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts.

• ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of measurability described above. However, if non-cystic lesions are present in the same subject, these are preferred for selection as target lesions.

1.3.3 Lesions with Prior Local Treatment

Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion.

1.4 Specifications by Methods of Measurements

1.4.1 Measurement of Lesions

All measurements should be recorded in metric notation (mm). All baseline evaluations should be performed as close as possible to the treatment start and never more than 30 days before the beginning of the treatment.

1.4.2 Method of Assessment

The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during follow-up. Imaging based evaluation should always be done rather than clinical examination unless the lesion(s) being followed cannot be imaged but are assessable by clinical exam.

1.4.2.1 CT/MRI Scan

CT/MRI is the best currently available and reproducible method to measure lesions selected for response assessment. Measurability of lesions on CT/MRI scan is based on the assumption that CT/MRI slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.
1.4.2.2 Chest X-ray

Chest CT is preferred over chest X-ray, particularly when progression is an important endpoint, since CT is more sensitive than X-ray, particularly in identifying new lesions. However, lesions on chest X-ray may be considered measurable if they are clearly defined and surrounded by aerated lung.

1.4.2.3 Clinical Lesions

Clinical lesions will only be considered measurable when they are superficial and ≥ 10 mm diameter as assessed using calipers. For the case of skin lesions, documentation by color photography including a ruler to estimate the size of the lesion is suggested. As previously noted, when lesions can be evaluated by both clinical exam and imaging, imaging evaluation should be undertaken since it is more objective and may also be reviewed at the end of the study.

1.4.2.4 Ultrasound

Ultrasound is not useful in assessment of lesion size and should not be used as a method of measurement. If new lesions are identified by ultrasound in the course of the study, confirmation by CT or MRI is advised.

1.4.2.5 Endoscopy, Laparoscopy

The utilization of these techniques for objective tumor evaluation is not advised.

1.4.2.6 Tumor Markers

Tumor markers alone cannot be used to assess objective tumor response.

2 BASELINE DOCUMENTATION OF ‘TARGET’ AND ‘NON-TARGET’ LESIONS

2.1 Target Lesions

When more than one measurable lesion is present at baseline all lesions up to a maximum of five lesions total (and a maximum of two lesions per organ) representative of all involved organs should be identified as target lesions and will be recorded and measured at baseline.

Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and should lend themselves to reproducible repeated measurements.

A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be included in the sum, then as noted below, only the short axis is added into the sum. The baseline sum diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease.
2.1.1 *Lymph Nodes*

*Lymph nodes* merit special mention since they are normal anatomical structures which may be visible by imaging even if not involved by tumor. Pathological nodes which are defined as measurable and may be identified as target lesions must meet the criterion of a *short axis of ≥ 15 mm by CT scan*. Only the *short* axis of these nodes will contribute to the baseline sum. Nodes that have a short axis < 10 mm are considered non-pathological and should not be recorded or followed.

2.2 *Non-target Lesions*

All other lesions (or sites of disease) including pathological lymph nodes should be identified as *non-target lesions* and should also be recorded at baseline. Measurements are not required and these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal progression’. In addition, it is possible to record multiple non-target lesions involving the same organ as a single item on the case record form (e.g. ‘multiple enlarged pelvic lymph nodes’ or ‘multiple liver metastases’).

3 TUMOR RESPONSE EVALUATION

3.1 Evaluation of Target Lesions

**Complete Response (CR):** Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

**Partial Response (PR):** At least a **30% decrease in the sum of diameters of target lesions**, taking as reference the baseline sum diameters.

**Progressive Disease (PD):** At least a **20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study** (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an **absolute increase of at least 5 mm**. *(Note: the appearance of one or more new lesions is also considered progression).*

**Stable Disease (SD):** Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

3.1.1 Special Notes on the Assessment of Target Lesions

3.1.1.1 *Lymph Nodes*

Lymph nodes merit special mention since they are normal anatomical structures which may be visible by imaging even if not involved by tumor. Pathological nodes which are defined as measurable and may be identified as target lesions must meet the criterion of a *short axis of ≥ 15 mm by CT scan*. Only the *short* axis of these nodes will contribute to the baseline sum. Nodes that have a short axis < 10 mm are considered non-pathological and should not be recorded or followed.
3.1.1.2 Target Lesions that Become ‘Too Small to Measure’

All lesions (nodal and non-nodal) recorded at baseline should have their actual measurements recorded at each subsequent evaluation, even when very small (e.g. 2 mm). If the radiologist is able to provide an actual measurement, that should be recorded, even if it is below 5 mm.

However, when such a lesion becomes difficult to assign an exact measure to then:

- If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm.
- If the lesion is believed to be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned (note: in case of a lymph node believed to be present and faintly seen but too small to measure, a default value of 5 mm should be assigned in this circumstance as well). This default value is derived from the 5 mm CT slice thickness (but should not be changed with varying CT slice thickness).

3.1.1.3 Target Lesions that Split or Coalesce on Treatment

- When non-nodal lesions ‘fragment’, the longest diameters of the fragmented portions should be added together to calculate the target lesion sum.
- As lesions coalesce, a plane between them may be maintained that would aid in obtaining maximal diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximal longest diameter for the ‘coalesced lesion’.

3.2 Evaluation of Non-target Lesions

While some non-target lesions may actually be measurable, they need not be measured and instead should be assessed only qualitatively at the time points specified in the protocol.

Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis).

Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.

Progressive Disease (PD): Unequivocal progression of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered progression).

3.2.1 Special Notes on Assessment of Non-target Lesions

The concept of progression of non-target disease requires additional explanation as follows:
3.2.1.1 When the Subject Also Has Measurable Disease

- To achieve ‘unequivocal progression’ on the basis of the non-target disease, there must be an overall level of substantial worsening in non-target disease such that, even in presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy.
- A modest ‘increase’ in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression status.

3.2.1.2 When the Subject Has Only Non-measurable Disease

- To achieve ‘unequivocal progression’ on the basis of the non-target disease, there must be an overall level of substantial worsening such that the overall tumor burden has increased sufficiently to merit discontinuation of therapy.
- A modest ‘increase’ in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression status.
- Because worsening in non-target disease cannot be easily quantified (by definition: if all lesions are non-measurable) a useful test that can be applied when assessing subjects for unequivocal progression is to consider if the increase in overall disease burden based on the change in non-measurable disease is comparable in magnitude to the increase that would be required to declare PD for measurable disease: i.e. an increase in tumor burden representing an additional 73% increase in ‘volume’ (which is equivalent to a 20% increase diameter in a measurable lesion). Examples include an increase in a pleural effusion from ‘trace’ to ‘large’, an increase in lymphangitic disease from localized to widespread, or may be described in protocols as ‘sufficient to require a change in therapy’.
- If ‘unequivocal progression’ is seen, the subject should be considered to have had overall PD at that point.

3.2.1.3 Tumor Markers

Tumor markers alone cannot be used to assess objective tumor responses. If markers are initially above the upper normal limit, however, they must normalize in order for a subject to be considered as having attained a complete response.

3.3 New Lesions

The appearance of new malignant lesions denotes disease progression. The finding of a new lesion should be unequivocal: i.e. not attributable to differences in scanning technique, change in imaging modality or findings thought to represent something other than tumor (for example, some ‘new’ bone lesions may be simply healing or flare of pre-existing lesions). This is particularly important when the subject’s baseline lesions show partial or complete response. For example, necrosis of a liver lesion may be reported on a CT scan report as a ‘new’ cystic lesion, which it is not.
A lesion identified on a follow-up study in an anatomical location that was *not* scanned at baseline is considered a new lesion and will indicate disease progression. An example of this is the subject who has visceral disease at baseline and while on study has a CT or MRI brain scan ordered which reveals metastases. The subject’s brain metastases are considered to be evidence of PD even if he/she did not have brain imaging at baseline.

If a new lesion is equivocal, for example because of its small size, continued therapy and follow-up evaluation will clarify if it represents truly new disease. *If repeat scans confirm there is definitely a new lesion, then progression should be declared using the date of the initial scan.*

### 3.3.1 FDG-PET Evaluation

While FDG-PET response assessments need additional study, it is sometimes reasonable to incorporate the use of the qualitative assessment of FDG-PET scanning to complement CT scanning in assessment of progression (particularly possible ‘new’ disease). New lesions on the basis of FDG-PET imaging can be identified according to the following algorithm:

- Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD based on a new lesion.
- No FDG-PET at baseline and a positive FDG-PET at follow-up:
  - If the positive FDG-PET at follow-up corresponds to a new site of disease confirmed by CT, this is PD.
  - If the positive FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up CT scans are needed to determine if there is truly progression occurring at that site (if so, the date of PD will be the date of the initial positive FDG-PET scan).
  - If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease on CT that is not progressing on the basis of the anatomic images, this is not PD.

### 4 RESPONSE CRITERIA

#### 4.1 Time Point Response

A response assessment should occur at each time point specified in the protocol.

For subjects who have *measurable disease* at baseline Table 1 provides a summary of the overall response status calculation at each time point.

<table>
<thead>
<tr>
<th>Table 1: Time Point Response: Subjects with Target (± Non-target) Disease</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Lesions</td>
<td>Non-target Lesions</td>
<td>New Lesions</td>
<td>Overall Response</td>
</tr>
<tr>
<td>CR</td>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>CR</td>
<td>Not evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>Target Lesions</td>
<td>Non-target Lesions</td>
<td>New Lesions</td>
<td>Overall Response</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------</td>
<td>-------------</td>
<td>------------------</td>
</tr>
<tr>
<td>PR</td>
<td>Non-PD or not all evaluated</td>
<td>No</td>
<td>PR</td>
</tr>
<tr>
<td>SD</td>
<td>Non-PD or not all evaluated</td>
<td>No</td>
<td>SD</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>Non-PD</td>
<td>No</td>
<td>NE</td>
</tr>
<tr>
<td>PD</td>
<td>Any</td>
<td>Yes or No</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>PD</td>
<td>Yes or No</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = not evaluable

### 4.1.1 Missing Assessments and Not Evaluable Designation

When no imaging/measurement is done at all at a particular time point, the subject is not evaluable (NE) at that time point. If only a subset of lesion measurements are made at an assessment, the case is also considered NE at that time point, unless a convincing argument can be made that the contribution of the individual missing lesion(s) would not have changed the assigned time point response.

### 4.1.2 Confirmation Scans

**Verification of Response:** Confirmation of response (CR or PR) is required. Confirmed CR or PR will be claimed only if the criteria for each are met at a subsequent timepoint (minimum 4 weeks after criteria for an objective response are first met).

**Verification of Progression:** Progression of disease should be verified in cases where progression is equivocal. If repeat scans confirm PD, then progression should be declared using the date of the initial scan. If repeat scans do not confirm PD, then the subject is considered not to have progressive disease per RECIST 1.1.

### 4.2 Best Overall Response: All Timepoints

The **best overall response** is determined once all the data for the subject is known. It is the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation. The subject’s best overall response assignment will depend on the findings of both target and non-target disease and will also take into consideration the appearance of new lesions.

Best response is defined as the best response across all time points (for example, a subject who has SD at first assessment, PR at second assessment, and PD on last assessment has a best overall response of PR).
When SD is believed to be best response, it must also meet the protocol specified minimum time from baseline. If the minimum time is not met when SD is otherwise the best time point response, the subject’s best response depends on the subsequent assessments. For example, a subject who has SD at first assessment, PD at second and does not meet minimum duration for SD, will have a best response of PD. The same subject lost to follow-up after the first SD assessment would be considered not evaluable.

Best response is defined as the best response across all time points with subsequent confirmation. Complete or partial responses may be claimed only if the criteria for each are met at a subsequent time point as specified in the protocol (generally 4 weeks later).

In this circumstance, the best overall response can be interpreted as specified in Table 2. When SD is believed to be best response, it must meet the protocol specified minimum time from baseline. Measurements must have met the SD criteria at least once after study entry at a minimum interval (in general not less than 6 - 8 weeks) that is defined in the study protocol.

<table>
<thead>
<tr>
<th>Overall response</th>
<th>Overall response</th>
<th>BEST overall response</th>
</tr>
</thead>
<tbody>
<tr>
<td>First time point</td>
<td>Subsequent time point</td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>CR</td>
<td>CR</td>
</tr>
<tr>
<td>CR</td>
<td>PR</td>
<td>SD, PD, or PR\textsuperscript{a}</td>
</tr>
<tr>
<td>CR</td>
<td>SD</td>
<td>SD provided minimum criteria for SD duration met, otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>PD</td>
<td>SD provided minimum criteria for SD duration met, otherwise, PD</td>
</tr>
<tr>
<td>CR</td>
<td>NE</td>
<td>SD provided minimum criteria for SD duration met, otherwise NE</td>
</tr>
<tr>
<td>PR</td>
<td>CR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>PR</td>
<td>PR</td>
</tr>
<tr>
<td>PR</td>
<td>SD</td>
<td>SD</td>
</tr>
<tr>
<td>PR</td>
<td>PD</td>
<td>SD provided minimum criteria for SD duration met, otherwise, PD</td>
</tr>
<tr>
<td>PR</td>
<td>NE</td>
<td>SD provided minimum criteria for SD duration met, otherwise NE</td>
</tr>
<tr>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
</tbody>
</table>

\textsuperscript{a} If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best response would depend on whether minimum duration for SD was met. However, sometimes ‘CR’ may be claimed when subsequent scans suggest small lesions were likely still present and in fact the subject had PR, not CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR.
4.3 Duration of Response

4.3.1 Duration of Overall Response

The duration of overall response is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded on study).

The duration of overall complete response is measured from the time measurement criteria are first met for CR until the first date that recurrent disease is objectively documented.

4.3.2 Duration of Stable Disease

Stable disease is measured from the start of the treatment (in randomized trials, from date of randomization) until the criteria for progression are met, taking as reference the smallest sum on study (if the baseline sum is the smallest, this is the reference for calculation of PD).